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ABSTRACT OF THE DISSERTATION
THE EFFECT OF VITAMIN D3 SUPPLEMENTATION ON BIOMARKERS OF
OXIDATIVE STRESS AND GLYCEMIC STATUS IN ADULTS WITH TYPE 2
DIABETES
by
Sahar Ajabshir
Florida International University, 2018
Miami, Florida
Professor Fatma G. Huffman, Major Professor
The aim of the present study was to assess the effect of 4000 IU and 6000 IU of daily
vitamin D3 supplementation for 3 months and 6 months on 8-hydroxy-2`deoxyguanosine (8-OHdG) and glycated albumin (GA%) among a group of individuals
with T2D and hypovitaminosis D. Furthermore, this study investigated the association
between dietary inflammatory index (DII), C-reactive protein (CRP), 8-OHdG,
hemoglobin A1C (HbA1c), GA% and insulin. Ninety participants were recruited by
community outreach and were screened. Sixty-eight participants met the inclusion criteria
were enrolled and completed the study. DII for each individuals was calculated based on
the values obtained from a validated food frequency questionnaire. Measurements of
variables were conducted at baseline, after 3 months and after 6 months of
supplementation. Serum CRP, 8-OHdg, GA%, HbA1c and insulin were measured by
enzymatic immunoassay methods. Mixed model was used to compare treatment groups.
Covariates in the adjusted model included age, gender, body mass index (BMI), insulin,
HbA1c, years with type 2 diabetes, perceived stress, physical activity, and sun exposure.
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Mean age was 54.94 ± 7.93 years. A multivariable linear regression model adjusted for
age, gender, waist circumference, and fasting plasma glucose was used to test for the
linear trend between DII and CRP, 8-OHdG, GA% and insulin. The unadjusted model
showed no significant associations between quartiles of DII, CRP, HbA1c and GA%. A
significant inverse association was observed between the fourth DII quartile and insulin level
(p=0.030). There was a significant association between SBP and DII in Q4 (p=0.029). The

unadjusted mean ± SD for 8-OHdG levels at baseline, after 3 and 6 months were 8068.94
± 2158.13 pg/mL, 9462.22 ± 2403.89 pg/mL, and 7412.69 ± 2031.68 pg/mL,
respectively. The unadjusted mixed model showed no difference between the 4000 and
6000 IU groups regarding the oxidative stress and GA%. Interactions between time and
treatment were not significant. The model showed a statistically significant difference in
8-OHdG level between baseline and 3 months (P<0.001), 3 months and 6 months
(P<0.001), and baseline and 6 months (P=0.016). The unadjusted mean ± SD for GA% at
baseline, 3 months and 6 months were 4.69 ± 1.7, 4.13 ± 1.09, and 4.42 ± 1.23,
respectively. Unadjusted pairwise comparisons between GA% were a statistically
significant from baseline to 3 months (P=0.015), and from 3 months to 6 months
(P=0.039), but not from baseline to 6 months (P= 0.488). The results of the present study
showed daily oral supplementation with higher doses of vitamin D for 6 months may
have beneficial effects on oxidative stress and glycemic status among a group of
individuals with type 2 diabetes and vitamin D deficiency/insufficiency. Furthermore,
pro-inflammatory dietary patterns may be associated with increased risk of
hyperinsulinemia and hypertension among individuals with T2D and hypovitaminosis D.
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CHAPTER I: INTRODUCTION
Diabetes mellitus is ranked as the seventh leading cause of death in the United
States (1). According to the 2014 National Diabetes Statistics Report by the Centers for
Disease Control and Prevention (CDC), over 29 million individuals (9.3% of the U.S
population) were diagnosed with diabetes while more than 8 million cases were
undiagnosed (2). As estimated by the American Diabetes Association in 2013, the total
direct and indirect costs of diabetes in the U.S. were $245 billion in 2012. Individuals
with diabetes had 2.3 times more medical expenditures compared to individuals without
diabetes (3). Native Americans had the highest rates of diagnosed diabetes (15.9%)
among all race/ethnic groups aged 20 years and older, followed by African Americans
(13.2%) and Hispanics (12.8%) (3). Type 2 diabetes accounts for 90-95% of all
diagnosed diabetes cases among adults. Insulin resistance and pancreatic Beta cell
dysfunction are the major pathophysiological abnormalities that lead to type 2 diabetes
pathogenesis and progression (4).
Insulin is a peptide hormone that unlocks the cells to absorb glucose from the
bloodstream and inhibits gluconeogenesis by the liver. Pancreatic Beta cells are
responsible for insulin production and secretion. Both decline in insulin sensitivity
(insulin resistance) and insufficient insulin production result in accumulation of excess
glucose in blood stream and starvation of the cells for glucose, which can lead to several
organ or system damages.
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Type 2 diabetes and inflammation
Insulin resistance and hyperglycemia are linked to systemic inflammation (5).
Inflammation is a defense mechanism of the innate immunity. As evidenced by a 9-year
case-cohort study of 10,275 adults, systemic inflammation precedes diabetes and low
grade inflammation plays a critical intermediary role in diabetogenesis (6). Accumulating
evidence suggest that type 2 diabetes is a condition of innate immune system and it may
be the result of long-term activation of an acute phase cytokine-mediated response of the
innate immune system (7). Although this acute phase reaction of the innate immune
system is initially stimulated to maintain homeostasis in response to environmental
stressors, it is suggested that the sustained activation of this mechanism may lead to
pathogenesis of many chronic inflammatory conditions such as type 2 diabetes (7). In this
process stressors, such as age, over-nutrition, physical inactivity, visceral adiposity and
oxygen metabolites stimulate the innate immune system such as adipose tissue
macrophages and monocytes to produce and release pro-inflammatory cytokines like
interleukin (IL)-1, IL-6, IL-18 and tumor necrosis factor-alpha (TNF-α) (8). Elevated
levels of pro-inflammatory cytokines elicit the liver to synthesize the acute phase
proteins, such as C-reactive protein (CRP), (8) while inducing dyslipidemia [increased
low density lipoproteins (LDL) and decreased high density lipoproteins (HDL)] by
hepatocytes (8). In addition, it is suggested that augmented cytokine levels elicit β-cell
apoptosis and result in β-cell dysfunction (9). Beside their effects on liver and pancreas,
pro-inflammatory cytokines stimulate the brain to release adrenocorticotropic hormone
which results in increased cortisol level (8). Cortisol is a glucocorticoid and hence is a
functional antagonist of insulin. While insulin diminishes hepatic gluconeogenesis,
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cortisol promotes gluconeogenesis and impedes the glucose uptake by insulin (10).
Cortisol directly suppresses the insulin release by the pancreatic β cells (10). Increased
cortisol is linked to insulin resistance, glucose intolerance and central obesity (11).
Systemic inflammation has been linked to oxidative stress (12). Increased ROS
production and impaired oxidative balance result in activation of nuclear factor κB (NFκB) which plays a critical regulatory role in immunity and inflammatory responses (13).
NF-κB regulates the expression of a variety of genes such as growth factors and proinflammatory cytokines such as IL-1β and TNF-α. NF-κB enhances a signaling cascade
which leads to sustained production of ROS and causes low grade inflammation (14). As
mentioned earlier, continued production of pro-inflammatory cytokines results in an
acute phase response by the innate immunity and lead to β cell apoptosis and dysfunction.
This process diminishes the ability of the pancreas to produce and release insulin and thus
contributes to type 2 diabetogenesis.
Nutrition plays a critical role in systemic inflammation regulation (15). It has
been shown that dietary patterns affect pro-inflammatory and anti-inflammatory
cytokines` balance and therefore enhance the risk of developing inflammatory diseases
(16). A comprehensive review of observational and prospective studies along with
randomized controlled trials suggested an anti-inflammatory property for Mediterranean
dietary pattern (higher consumption of fruits and vegetables, unrefined carbohydrates,
and fish, moderate consumption of dairy products and wine, and low consumption of
non-fish meat) (17), compared to Western diet (higher consumption of refined
carbohydrates, saturated fat, and red meat) (18). Consumption of antioxidant vitamins,
such as vitamin C, E, and β-Carotene, and polyunsaturated fatty acids (PUFA), such as
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Omega-3 fatty acids, have been linked to lower systemic inflammation (19), while higher
intakes of total and saturated fat have been associated with higher systemic inflammation
(20-21).
Dietary inflammatory index
Dietary Inflammatory Index (DII) is a comprehensive literature-derived tool first
developed by Caviccia et al. (22) in 2009 to assess the inflammatory potential of each
individual's diet. Out of 2700 screened articles published from 1950 to 2007, 929 were
considered for developing the algorithm to formulate DII. The objective of this project
was to develop a methodology which could quantify dietary intake on a spectrum of
maximally anti-inflammatory to maximally pro-inflammatory Caviccia at al. (22)
validated the DII scores against CRP. The results of the validation study showed a
significant relationship between DII, as a categorical variable, and CRP. Later in 2013,
DII was updated by Shivappa et al. (23). The updated DII, is based on 1943 articles , out
of 6500 screened, published in 2010-2013 in regards to the effect of diet on 6
inflammatory biomarkers (IL-1β, IL-4, IL-6, IL-10, TNF-α, and CRP). The updated DII
include forty-five pro-inflammatory and anti-inflammatory food parameters, compared to
forty-two in the initial DII. The food parameters include: alcohol, vitamin B12, vitamin
B6, β-Caroten, caffeine, carbohydrate, cholesterol, energy, eugenol, total fat, fibre, folic
acid, garlic, ginger, iron, magnesium, monounsaturated fatty acids (MUFA), niacin, n-3
fatty acids, n-6 fatty acids, onion, protein, PUFA, riboflavin, saffron, saturated fat,
selenium, thiamin, trans fat, tumeric, vitamin A, vitamin C, vitamin D, vitamin E, zinc,
green/black tea, flavan-3-ol, flavones, flavonols, flavonones, anthocyanidins, isoflavones,
pepper, thyme/oregano, rosemary. After fitting the DII to eleven dietary intake data sets
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from across the world, the globally adjusted scores ranged from +7.98 (maximally proinflammatory) to -8.87 (maximally anti-inflammatory). High DII values (proinflammatory diet) have been linked to low grade inflammation and insulin resistance
(24), metabolic syndrome (25), cardiovascular diseases (26), colorectal cancer (27-28),
pancreatic cancer (29), gastric cancer (30), and ovarian cancer (31).
Type 2 diabetes and oxidative stress
Oxidative stress is caused by an imbalance between oxygen metabolites
production and ability of the endogenous and exogenous antioxidant networks to
neutralize them (32). Reactive oxygen species (ROS), such as superoxide anion (O 2−),
hydrogen peroxide (H2O2), hydroxyl radical (OH°) and peroxynitrite (OONO−), have one
or more unpaired electrons and are highly reactive (33). ROS may attack other molecules
to take an electron from them and stabilize (34). They can damage proteins, lipids and
DNA. These oxidized biomolecules may trigger further oxidizing chain reactions that
may result in production of new free radicals (34-35). Oxidative stress plays a pivotal
role in systemic inflammation, type 2 diabetes development and its related complications
(36). Although ROS production is one of the primary defense mechanisms, increased
ROS production may result in impaired oxidative balance which leads to activation of
nuclear factor κB (NF-κB). NF-κB plays a critical regulatory role in immunity and
inflammatory responses (35). NF-κB regulates the expression of a variety of genes such
as growth factors and pro-inflammatory cytokines and enhances a signaling cascade
which leads to sustained production of ROS and causing low grade inflammation (37).
Continued production of pro-inflammatory cytokines results in an acute phase response
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by the innate immunity and lead to pancreatic β cell apoptosis and dysfunction. This
process diminishes the ability of the pancreas to produce and release insulin and thus
causes type 2 diabetes.
ROS induced oxidation of guanine residues of DNA can damage the DNA strands
and produce 8-hydroxyguanosine (8-OHdG) (38). Several studies had shown increased 8OHdG levels among individuals with type 2 diabetes (39-40). It has been suggested that
8-OHdG may be a predictive biomarker for early detection of lifestyle related health
conditions, such as type 2 diabetes, at population level (41).
Nutrition plays a vital role in maintaining the oxidative balance. The direct effect
of nutrition is via providing dietary antioxidants to the exogenous antioxidant network. In
addition, nutrition affects the oxidative balance indirectly by providing energy to the
endogenous enzymatic antioxidant system and therefore enhances its function (34). On
the other hand, over-nutrition and physical inactivity are stressors that contribute to ROS
production by inducing hyperglycemia and increased glucose accumulation in the muscle
tissue, adipose tissue and pancreatic cells (33). ROS formed by autoxidation of glucose in
the muscle tissue, adipose tissue, and pancreatic cells may non-enzymatically react with
proteins and result in further production of ROS (42). These pathogenic effects can lead
to development of insulin resistance, Beta cell dysfunction and glucose intolerance and
thus result in type 2 diabetogenesis. In animal models ROS impaired insulin synthesis via
suppression of insulin gene expression in pancreatic Beta cells (37). Antioxidant
treatment in diabetic rats resulted in improved insulin secretion (37). It has been
suggested that improvement in oxidative stress may have beneficial effects on the health
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of individuals with type 2 diabetes (33), and that antioxidant therapy may be a potential
solution to reduce type 2 diabetes-related complications (37).
Oxidative stress and vitamin D
The antioxidant properties of vitamin D3 in human under diabetes conditions are
not clear. One potential anti-oxidative action of vitamin D may be via suppression of
intracellular NF-κB which result in down-regulation of pro-inflammatory cytokines (43).
Diminished pro-inflammatory cytokine levels prevent B cell apoptosis and improves B
cell survival (36). In addition 1,25(OH)2D3, known as the active form of vitamin D3,
activates the expression of anti-inflammatory cytokines such as IL-4, IL-10 and TGF-B1
(44). Deluca et al. (44) suggested that vitamin D may have an immunosuppressive
properties due to its effect on regulation of pro-inflammatory and anti-inflammatory
cytokines. Vitamin D supplementation could decrease oxidative stress in human
colorectal mucosa as measured by 8-OHdG (35). Furthermore, 1,25(OH)2D3 is proved to
have protective properties against UV-induced oxidative DNA damage in skin cells (46).
Sun exposure have been shown to be a critical factor in maintaining serum
vitamin D level in human (47). It has been reported that exposed skin areas` color, such
as forearm skin color, are significantly associated with serum 25(OH)D3 and that forearm
skin color may be an accurate predictor of serum vitamin D (47). Several studies showed
that lighter skin color is associated with higher serum 25(OH)D3 levels (47-50).
Considering the antioxidant properties of vitamin D and the role of sun exposure in
maintaining the serum vitamin D level, further investigations are required to assess the
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association between skin color and oxidative stress under hypovitaminosis D and diabetes
conditions.
Type 2 diabetes and early glycation products
Persistent hyperglycemia leads to non-enzymatic glycation of proteins, known as
Maillard reaction. In this reversible process the carbonyl group of reducing sugars, such
as glucose, binds to the amino group on lysine residues of proteins, such as hemoglobin,
and form early glycation products known as Schiff-bases and Amadori adducts (51).
Early glycation leads to formation of intermediate glycation products (IGPs) such as
glycated hemoglobin (HbA1c) and glycated albumin (GA). Continuous elevation in IGP
level can lead to their irreversible rearrangement to stable advanced glycation end
products (AGEs) (51-52). AGEs accumulation is a measure of carbonyl, metabolic and
oxidative stress and serve as a long term metabolic memory, rather than short term
glycemic control. In contrast, IGPs are better indicators of glycemic control (52).
Amadori adducts, the major form of IGPs, have 2-3 times higher concentrations of
glycated products than AGEs (53). HbA1c is currently an established gold standard
Amadori adduct, reflecting the glycemic control over the period of 8-12 weeks. In
addition HbA1c is associated with the risk of chronic diabetes related complications such
as neuropathy, nephropathy, retinopathy and coronary artery disease (53-54). HbA1c
level, however, can be affected by several factors such as red blood cells turnover,
uremia, erythropoietin treatment, blood transfusion, anemia, renal malfunction, and irondeficiency (53). Based on the twin studies by Sneider et al. (55), HbA1c is strongly
inherited and influenced by genetics. Furthermore HbA1c reflects on the glycemic
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control inside the RBCs while serum protein glycation reflects glycemic control in the
extracellular space (56).
Albumin is the most abundant protein in plasma and makes more than 50% of
plasma proteins (57). With a half-life of 14-21 days, albumin is known as the main
extracellular antioxidant and plays a fundamental role in maintaining the oxidative
balance (58). Furthermore, albumin has anti-inflammatory and anti-thrombotic properties
and plays a crucial role in transportation of nutrients, metabolites, hormones and drugs
while maintaining the osmotic pressure (53). As a protein with 59 lysine residues,
albumin is widely involved in extracellular Maillard reactions under hyperglycemic
conditions (53). Non-enzymatic glycation of albumin happens 10 times faster and 9 times
more than non-enzymatic glycation of hemoglobin in-vivo (59). It is suggested that
glycated albumin (GA) may be a more accurate indicator of short term glycemic control
among individuals with type 1 and type 2 diabetes (60). GA has been linked to diabetes
induced complications including nephropathy, neuropathy and arteriosclerosis (57).
Although as compared to hemoglobin, serum albumin is less affected by RBC turnover,
erythropoietin treatment, blood transfusion, anemia, and iron-deficiency; albumin
turnover, hepatic cirrhosis and renal malfunction can enhance serum albumin level. It is
suggested GA/HbA1c ratio may be a better index of glycemic control among individuals
with diabetes (60).
Fructosamine is the measure of a combination of circulating glycated proteins,
such as glyco-lipoproteins and glyco-globlulins (61-62). Knowing albumin is the most
abundant protein in serum, fructosamine is predominately reflecting GA, however, GA%
may provide a more accurate and efficient measure of extracellular glycation status over
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2-3 weeks (62). Furthermore, in case of abnormal albumin levels, fructosamine values
must be adjusted to albumin levels (62).
Oxidative stress, inflammation and glycated albumin
Albumin structure and antioxidant function is greatly suppressed by the Maillard
reaction. Amadori GA is in fact a stimulant for oxidative stress by producing oxygen free
radicals and lipid peroxides. Non-enzymatic glycation of albumin also suppresses its
nutrient/metabolite/drug binding affinity and diminishes its transportation ability (58). In
macrophage RAW cells (a commercial murine cell-line), GA induced oxidative stress
activated extracellular signal-regulated kinase (ERK), influenced TGF-β1 production and
activated NF-κB which plays a critical regulatory role in immunity and inflammatory
responses (63). In diabetic human endothelial cells, GA increased oxidative stress and
ROS production by up-regulating NADPH oxidase (64). This may help to understand the
role of Amadori-adducts in pathogenesis of diabetes-induced vascular complications.
Exposure of diabetic mice adipocytes to GA resulted in increased oxidative stress,
accumulation of ROS in these cells and oxidation of proteins inside them (65). GAderived glycation end products (AGEs) may lead to adipocytes dysfunction and insulin
resistance in adipose tissue.
Type 2 diabetes and vitamin D
It has been shown that both, vitamin D deficiency and type 2 diabetes, have
several risk factors in common: aging, being overweight, having a sedentary lifestyle, and
being African-American or Hispanic (66). In addition, seasonal variations have been
observed for both serum vitamin D [25(OH)D3] levels and insulin concentrations
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suggesting a potential relationship between serum 25(OH)D3 and development of type 2
diabetes (67-69). Vitamin D directly affects insulin sensitivity, Beta cell function, insulin
secretion and hence mediates glucose homeostasis (66). Several studies reported an
association between lower serum vitamin D levels and increased risk of developing type
2 diabetes (70-72). In addition, a high prevalence of hypovitaminosis D has been
observed among individuals diagnosed with type 2 diabetes, compared to individuals
without type 2 diabetes (73). Beside its effect on Beta cell function and insulin
sensitivity, vitamin D also regulates calcium homeostasis which plays an important role
in regulating insulin secretion (74).
An extensive review with a meta-analyses, proposed that the direct role of vitamin
D on glucose homeostasis is mediated via binding of its metabolically active form,
1,25(OH)2D3, to the vitamin D receptors (VDR) in pancreatic Β-cells, activation of
25(OH)D3 to 1,25(OH)2D3 by the enzyme 1-α-hydroxylase (expressed in B-cells) within
B-cells, stimulating the insulin receptor gene transcription, enhancing the expression of
insulin receptor and hence affecting the insulin-mediated glucose transport (68). VDRs
also exist in skeletal muscle and adipose tissues which are insulin targets and are
responsible for peripheral insulin sensitivity. VDR expression in human skeletal muscle
tissue, which declines with age, stimulates regulation of protein synthesis and results in
diminished insulin sensitivity among older adults (75). In addition, animal studies
showed impaired insulin secretion in mice with inactive VDRs (76).
The indirect role of vitamin D in glucose homeostasis is determined by its effect
on regulation of extracellular calcium and calcium flux in the pancreatic B-cells (68).
Imbalance between the extracellular and intracellular calcium pools influences the ability
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of B-cells to release insulin. Serum vitamin D concentration is inversely associated with
Parathyroid hormone (PTH) level, which regulates intracellular calcium (77). In animal
and in-vitro study, hypovitaminosis D was found to cause augmented PTH levels, which
resulted in elevated intracellular calcium levels (78). In adipose tissue (an insulin target
tissue), sustained augmentation in cytosolic calcium level was associated with increased
insulin resistance (78). The insulin mediated glucose uptake was decreased by 30%
among PTH injected rats (68). This could be due to increased phosphorylation of GLUT4 (an insulin-regulated glucose transporter in adipose and muscle tissue) in the presence
of elevated cytosolic calcium levels. Cross-sectional studies reported an inverse relation
between serum vitamin D level and insulin sensitivity (79-81). In addition, vitamin D and
calcium supplementation attenuated insulin resistance among non-diabetic older adults
with impaired fasting plasma glucose (FPG) (82).
Vitamin D and glycated albumin
The relationship between vitamin D and GA is yet to be studied. Furthermore, to
our knowledge no studies have yet investigated the effectiveness of vitamin D3
supplementation on GA, as a biomarker of short-term glycemic control, among
individuals with or without diabetes. Despite lack of evidence on the relationship
between GA and vitamin D, HbA1c have been negatively linked to serum 25(OH)D level
(83-85). Clinical trials on vitamin D supplementation and its impact on glycemic
improvement (specifically on HbA1c) among individuals with type 2 diabetes, however,
could not consistently support the effectiveness of vitamin D supplementation on
glycemic control (86). It is not clear whether improvement in serum vitamin D may
improve Amadori formation of GA. We assume vitamin D may improve GA level via its
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antioxidant properties. Furthermore, since vitamin D has a high binding affinity for
adipose tissue, it may prevent the GA-induced oxidative stress in adipocytes via its
antioxidant capabilities. Albumin is a transporter of vitamin D; therefore, binding of
vitamin D to serum albumin may affect its affinity to glucose under non-enzymatic
conditions. In that case, vitamin D may be effective in prevention of GA-derived AGEs
production.
Significance of the study
Effectiveness of vitamin D3 supplementation on DNA/RNA oxidative stress
under type 2 diabetes condition in human is not clear. Trials among human subjects are
needed to investigate and quantify the potential beneficial impact of vitamin D3
supplementation at different dosages among individuals with vitamin D deficiency.
Therefore the aim of this study was to investigate the effect of 4000 IU and 6000 IU daily
supplementation of vitamin D3 for 3 and 6 months on biomarkers of DNA/RNA
oxidative stress, 8-OHdG, in individuals with type 2 diabetes and serum vitamin D
[25(OH)D3] insufficiency or deficiency. In addition, we investigated the relationship
between skin exposure score, as a measure of sun exposure, and oxidative stress in
individuals with type 2 diabetes and 25(OH)D3 deficiency or insufficiency. We
hypothesized that daily supplementation with 4000 and 6000 IU of vitamin D3 for 6
months will decrease serum 8-OHdG level in individuals with type 2 diabetes and
vitamin D insufficiency or deficiency, compared to baseline. To our knowledge, this is
the first study investigating the effects of vitamin D3 supplementation on 8-OHdG among
human subjects with type 2 diabetes. Furthermore, we hypothesized individuals with
lighter forearm skin color will have lower 8-OHdG levels compared to those with darker
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forearm skin color, at baseline and that individuals with higher skin exposure scores, as
measured by the difference between exposed and unexposed skin colors, will have lower
8-OHdG levels.
To our knowledge, there is currently no studies that assessed the possible effects
of vitamin D3 supplementation on serum GA levels among individuals with or without
type 2 diabetes. While GA is a relatively new biomarker for type 2 diabetes management,
almost all the current studies on vitamin D supplementation in type 2 diabetes have been
targeting fasting plasma glucose and HbA1c as the markers of glycemic control. The
findings of this study will help to fill the gap on the possible beneficial effects of vitamin
D3 on GA, as the most abundant Amadori-protein in human serum. Therefore, the aim of
this study was to investigate the effectiveness of daily supplementation with 4000 IU and
6000 IU vitamin D3 for 3 months and 6 months on GA.
Furthermore, this study was aimed to assess the relationship between DII and
biomarker of inflammation (CRP), oxidative stress (8-OHdG), glycemic status [glycated
hemoglobin (HbA1c) and glycated albumin (GA)] and insulin level among individuals
with type 2 diabetes and vitamin D deficiency/insufficiency. To our knowledge this is the
first study assessing the relationship between DII, 8-OHdG, HbA1c, GA and insulin
among individuals with type 2 diabetes and vitamin D deficiency/insufficiency.
Specific aims and hypothesis
Specific aim 1:
To investigate the association between dietary inflammatory biomarker (DII) and
biomarker of inflammation (CRP), oxidative stress (8-OHdG), glycemic status [glycated
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hemoglobin (HbA1c) and glycated albumin (GA)] and insulin level among individuals
with type 2 diabetes and vitamin D deficiency/insufficiency.
Hypothesis: DII is positively associated with serum CRP, 8-OHdG, GA%, HbA1c
and inversely associated with insulin level.
Specific aim 2:
To investigate the effect of 4000 and 6000 IU/day of vitamin D3 supplementation
for 6 months on biomarker of oxidative stress (8-hydroxy-2`-deoxyguanosine) in
individuals with type 2 diabetes and serum vitamin D insufficiency/deficiency.
Hypothesis: Daily supplementation with 4000 and 6000 IU of vitamin D3 for 6
months will decrease serum 8-OHdG level in individuals with type 2 diabetes and
vitamin D insufficiency/deficiency, compared to baseline.
Specific aim 3:
To investigate the effect of 4000 and 6000 IU/day of vitamin D3 supplementation
for 6 months on biomarker of glycemic status [glycated albumin (GA%)] in individuals
with type 2 diabetes and serum vitamin D insufficiency/deficiency.
Hypothesis: Daily supplementation with 4000 and 6000 IU of vitamin D3 for 6
months will decrease serum GA% in individuals with type 2 diabetes and vitamin D
insufficiency/deficiency, compared to baseline.
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CHAPTER II: ASSOCIATION BETWEEN DIETARY INFLAMMATORY
INDEX AND SERUM VITAMIN D, OXIDATIVE STRESS, INFLAMMATION,
AND GLYCEMIC STATUS IN ADULTS WITH TYPE 2 DIABETES
Introduction
Diabetes mellitus is ranked as the seventh leading cause of death in the United
States (1). According to the 2014 National Diabetes Statistics Report by the Centers for
Disease Control and Prevention (CDC), over 29 million individuals (9.3% of the U.S
population) were diagnosed with diabetes while more than 8 million cases were
undiagnosed (2). As estimated by the American Diabetes Association in 2013, total direct
and indirect costs of diabetes in the U.S. were $245 billion in 2012. Individuals with
diabetes had 2.3 times more medical expenditures compared to individuals without
diabetes (3). Native Americans had the highest rates of diagnosed diabetes (15.9%)
among all race/ethnic groups aged 20 years and older, followed by African Americans
(13.2%) and Hispanics (12.8%) (3). Type 2 diabetes accounts for 90-95% of all
diagnosed diabetes cases among adults. Insulin resistance and pancreatic Beta cell
dysfunction are the major pathophysiological abnormalities that lead to type 2 diabetes
pathogenesis and progression (4).
Insulin is a peptide hormone that unlocks the cells to absorb glucose from the
bloodstream and inhibits gluconeogenesis by the liver. Pancreatic Beta cells are
responsible for insulin production and secretion. Both decline in insulin sensitivity
(insulin resistance) and insufficient insulin production result in accumulation of excess
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glucose in blood stream and starvation of the cells for glucose, which can lead to several
organ or system damages.
Insulin resistance and hyperglycemia are linked to systemic inflammation (5).
Inflammation is a defense mechanism of the innate immunity. As evidenced by a 9-year
case-cohort study of 10,275 adults, systemic inflammation precedes diabetes and lowgrade inflammation plays a critical intermediary role in diabetogenesis (6). Accumulating
evidence suggest that type 2 diabetes is a condition of innate immune system, and it may
be the result of long-term activation of an acute phase cytokine-mediated response of the
innate immune system (7). Although this acute-phase reaction of the innate immune
system is initially stimulated to maintain homeostasis in response to environmental
stressors, it is suggested that the sustained activation of this mechanism may lead to
pathogenesis of many chronic inflammatory conditions, including type 2 diabetes (7). In
this process, stressors such as age, over-nutrition, physical inactivity, visceral adiposity
and oxygen metabolites stimulate the innate immune system comprised of adipose tissue
macrophages and monocytes to produce and release pro-inflammatory cytokines such as
interleukin (IL)-1, IL-6, IL-18 and tumor necrosis factor-alpha (TNF-α) (8). Elevated
levels of pro-inflammatory cytokines elicit the liver to synthesize the acute phase
proteins, such as C-reactive protein (CRP), while inducing dyslipidemia [increased low
density lipoproteins (LDL) and decreased high density lipoproteins (HDL)] by
hepatocytes (8). In addition, it is suggested that augmented cytokine levels elicit β-cell
apoptosis and result in β-cell dysfunction (9). Furthermore, pro-inflammatory cytokines
stimulate the brain to release adrenocorticotropic hormone, which results in increased
cortisol level (8). Cortisol is a glucocorticoid that is a functional antagonist of insulin.
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While insulin diminishes hepatic gluconeogenesis, cortisol promotes gluconeogenesis
and impedes the glucose uptake by insulin (10). Cortisol directly suppresses the insulin
release by the pancreatic β cells (10). Increased cortisol is linked to insulin resistance,
glucose intolerance and central obesity (11).
Systemic inflammation has been linked to oxidative stress (12). Increased
Reactive Oxygen Species (ROS) production and impaired oxidative balance result in
activation of nuclear factor κB (NF-κB), which plays a critical regulatory role in
immunity and inflammatory responses (13). NF-κB regulates the expression of a variety
of genes such as growth factors and pro-inflammatory cytokines such as IL-1β and TNFα. NF-κB enhances a signaling cascade which leads to sustained production of ROS and
causes low grade inflammation (14). As mentioned earlier, continued production of proinflammatory cytokines results in an acute phase response by the innate immunity and
lead to β cell apoptosis and dysfunction. This process diminishes the ability of the
pancreas to produce and release insulin and thus contributes to type 2 diabetogenesis.
Nutrition plays a critical role in systemic inflammation regulation (15). It has
been shown that dietary patterns affect pro-inflammatory and anti-inflammatory
cytokines’ balance and therefore enhance the risk of developing inflammatory diseases
(16). A comprehensive review of observational and prospective studies, along with
randomized controlled trials, suggested an anti-inflammatory property for the
Mediterranean dietary pattern (higher consumption of fruits and vegetables, unrefined
carbohydrates, and fish, moderate consumption of dairy products and wine, and low
consumption of non-fish meat (17), compared to the Western diet (higher consumption of
refined carbohydrates, saturated fat, and red meat) (18). Consumption of antioxidant
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vitamins, such as vitamin C, E, and β-Carotene, and polyunsaturated fatty acids (PUFA),
such as Omega-3 fatty acids, have been linked to lower systemic inflammation (19),
while higher intakes of total and saturated fat have been associated with higher systemic
inflammation (20-21).
The Dietary Inflammatory Index (DII) is a comprehensive literature-derived tool
that was first developed by Caviccia et al. (22) in 2009 to assess the inflammatory
potential of each individual's diet. Out of 2700 screened articles published from 1950 to
2007, 929 were considered for the development of the algorithm to formulate DII. The
objective of this project was to develop a methodology which could score dietary intakes
on a spectrum of maximally anti-inflammatory to maximally pro-inflammatory (22).
Caviccia at al. validated the DII scores against CRP. The results of the validation study
showed a significant relationship between DII, as a categorical variable, and CRP (22).
Later in 2013, DII was updated by Shivappa et al. (23). The updated DII, is based on
1943 articles out of 6500 screened, published in 2010-2013 in regards to the effect of diet
on 6 inflammatory biomarkers (IL-1β, IL-4, IL-6, IL-10, TNF-α, and CRP). The updated
DII includes forty-five pro-inflammatory and anti-inflammatory food parameters,
compared to forty-two in the initial DII. The food parameters include: alcohol, vitamin
B12, vitamin B6, β-Carotene, caffeine, carbohydrate, cholesterol, energy, eugenol, total
fat, fiber, folic acid, garlic, ginger, iron, magnesium, monounsaturated fatty acids
(MUFA), niacin, n-3 fatty acids, n-6 fatty acids, onion, protein, PUFA, riboflavin,
saffron, saturated fat, selenium, thiamin, trans fat, turmeric, vitamin A, vitamin C,
vitamin D, vitamin E, zinc, green/black tea, flavan-3-ol, flavones, flavonols, flavonones,
anthocyanidins, isoflavones, pepper, thyme/oregano, rosemary. After fitting the DII to
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eleven dietary intake data sets from across the world, the globally adjusted scores ranged
from +7.98 (maximally pro-inflammatory) to -8.87 (maximally anti-inflammatory). High
DII values (pro-inflammatory diet) have been linked to low grade inflammation and
insulin resistance (24), metabolic syndrome (25), cardiovascular diseases (26), colorectal
cancer (27-28), pancreatic cancer (29), gastric cancer (30), and ovarian cancer (31).
The aim of this study was to assess the relationship between DII and biomarker of
inflammation (CRP), oxidative stress [8-hydroxydeoxyguanosine (8-OHdG)], glycemic
status [glycated hemoglobin (HbA1c) and glycated albumin (GA)] and insulin level
among individuals with type 2 diabetes and vitamin D deficiency/insufficiency. To our
knowledge this is the first study assessing the relationship between DII, 8-OHdG,
HbA1c, GA and insulin among individuals with type 2 diabetes and vitamin D
deficiency/insufficiency.
Materials and methods:
This is an ancillary study of data from the parent study by Huffman et al. (32) that
investigated the effects of vitamin D3 supplementation on cardiovascular disease
biomarkers. The outcome of this study is explained in detail elsewhere (32).
The study design is described below:
Study participants were recruited from 2 sources: 1) Community areas by
distributing flyers that included the purpose of the study, inclusion and exclusion criteria,
and the investigators information. 2) The Borinquen Health Care Center and the Clinical
Care Medical Center. Weekly visits were conducted to recruit study participants.
Interested individuals called the investigators and expressed their willingness to
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participate in the study, and were asked to answer a few eligibility pre-screening
questions. Qualified individuals were invited for screening at the Human Nutrition
Laboratory, Florida International University. After signing the informed consent form,
fasting blood samples were collected, and screening questionnaires were administered to
evaluate whether the inclusion criteria were met (33).
The inclusion criteria were being 30-70 years old, being African-American or
Hispanic, having Type 2 diabetes, and being vitamin D insufficient [25(OH)D3 < 30
ng/mL]. Exclusion criteria were being pregnant or lactating, taking vitamin D
supplements, injecting insulin, suffering from thyroid, hepatic and/or renal complications,
and suffering from HIV and cancer. Participants of the current study were contacted at
two-time points:
Screening: During screening the eligibility of the participants to enroll in the
study was assessed based on the inclusion and exclusion criteria. Participants signed an
informed consent form before the start of data collection. Fasting blood was collected for
screening of vitamin D status.
Baseline: All participants who met the inclusion criteria participated in the study.
Blood collection, anthropometric measurements, Willett food frequency questionnaire
and a socio-demographic questionnaire were administered at baseline.
Measurements of variables:
a. Socio-demographic questionnaire
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A socio-demographic questionnaire was used to collect information about age,
gender, race/ethnicity, years living in the United States and years having type 2 diabetes.
b. Anthropometric measurements
Height and weight measurements were taken by using a SECA balance scale
(SECA Corp, Columbia, MD), to the nearest 0.5 cm and 0.1 kg, respectively. Waist
circumference was measured by using a measuring tape to the nearest 0.1 cm. Systolic
and diastolic blood pressure were measured in a sitting position by using an automated
arm-cuff monitor. All measurements were done twice and the average of two readings
was included in the analysis.
c. Dietary intake
A food frequency questionnaire (FFQ) developed by Willett et al. (34) was used
to assess dietary intake for each individual. This questionnaire was validated previously
among individuals from different racial and ethnic backgrounds (34-37). In a study
among Cuban-Americans, Nath et al. (35) validated Willet FFQ against a 3-day food
record and reported no significant differences in the nutrient intakes estimated by these
two methods. Ethnic food items were added to the questionnaire. This study suggested
Willet FFQ may be a reasonable tool for estimating macronutrients and alcohol among
Cuban-Americans (35). In the present study participants self-reported their average
consumption of 131 food items for the past 12 months. Frequency of intake for each food
item was ranged from ‘‘never’’ to ‘‘6 times or more daily’’. Consumption of
multivitamin and mineral supplements were also recorded. In order to calculate each
individuals’ macronutrient and micronutrient intake, the frequency of consumption of
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each food item was multiplied by its nutrient value (Harvard University Food
Consumption Data Base, Channing Laboratory, Boston, MA).
d. Calculation of the dietary inflammatory index (DII) score
DII for each individual was calculated based on the values obtained from the
Willett FFQ. In this process, thirty-four foods and constituents parameters were included
in the analysis (Table 1). To obtain a ‘z score’ relative to standard global mean, estimated
intake of each food parameter for each individual was subtracted from the global standard
mean and then divided by the global standard deviation. To prevent possible right
skewing, calculated z-scores were converted to a percentile score centered on 0; First a
percentile ranking was calculated for each z score and then each value was multiplied by
2 and subtracted by 1 to obtain values range between -1 and +1. The calculated centered
score for each food item was then multiplied by the respective food parameter’s specified
inflammatory effect score (23). All the obtained food parameter scores for each
participant were summed up to create the overall DII score for each individual. More
positive scores reflect more pro-inflammatory dietary intakes.
e. Blood collection and analysis
Fasting venous blood was collected by a certified phlebotomist (15 mL). After
coagulation of blood samples in serum separator tubes for 30-45 minutes, samples were
centrifuged at 2500 RPM for 30 minutes to obtain the serum. Fasting plasma glucose
concentration was measured by hexokinase enzymatic method, glycated hemoglobin A1c
(HbA1c) was measured by using DCA2000 + system (BAYER Corporation, Diagnostics
Division, N.Y) and 25(OH)D3 concentrations were measured by using an enzymatic
immunoassay kit (Immunodiagnostic Systems Scottsdale, AZ). Oxidative stress
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biomarker, 8-hydroxydeoxyguanosine (8-OHdG), was assessed using a human
DNA/RNA oxidative damage competitive enzyme-linked immunosorbent assay (Cayman
Chemical, Ann Arbor, MI, item No 589320).
Statistical analysis:
The IBM statistical package for the social sciences (SPSS) version 20 (Chicago,
IL, USA) was used for performing the statistical analysis. P-value ≤0.05 was considered
significant (two-tailed). DII score was categorized into quartiles: Q1 (-5.214, -1.827), Q2
(-1.826, -0.653), Q3 (-0.652, +1.138), Q4 (+1.138, +3.999). Descriptive statistics were
conducted for baseline characteristics; for continuous variables means and standard errors
(SE) and for categorical variables frequencies/percentages were determined. Pearson
correlation analysis was used to assess the correlation between variables within each
quartile. Linear regression analysis was used to test the association between DII versus
CRP, DII versus 8-OHdG, and DII versus GA% within each quartile. The multivariable
model was later adjusted for confounders.
Results:
Out of 92 individuals who were screened at baseline, 77 met the inclusion criteria
and participated in the interventions. Nine subjects were excluded due to missing values
for 8-OHdG and GA%. Sixty-eight participants, 41 females and 27 males, were included
in the current analysis. Baseline characteristics of participants for the entire sample and
for each quartile [Q1 (-5.214, -1.827), Q2 (-1.826, -0.653), Q3 (-0.652, +1.138), Q4
(+1.138, +3.999)] are shown in table 2. There were 17 participants in each quartile. Mean
age was 54.94 ± 7.93 with 60.3 % of participants being female. Participants in the first

32

quartile of DII (the least pro-inflammatory diet) were more likely to be women and had
the highest systolic blood pressure (SBP). Participants in the third percentile of DII were
more likely to be female, had higher BMI scores and higher CRP, HbA1c and fasting
plasma glucose (FPG) levels. Participants in the fourth percentile of DII (more proinflammatory diet) were less likely to be female, had higher 8-OHdG, GA%, HbA1c,
FPG and parathyroid hormone (PTH).
Pearson correlation analysis showed a statistically significant correlation between
DII Q1 and BMI (r=0.520, p=0.033), and PTH (r=0.510, p=0.037). For DII Q2, there
was a significant correlation between DII score and HbA1c (r=0.529, p=0.029). For DII
Q3, there was a significant correlation between DII score and insulin level (r=0.620,
p=0.008). For DII Q4, there was a significant correlation between DII score and SBP
(r=0.532, p=0.0.028). Linear regression models assessing the association between
quartile DII scores and BMI, PTH, HbA1c, insulin, and SBP were conducted (table 3).
The unadjusted model showed no significant associations between DII, HbA1c and PTH
(Q1-Q4). There was a marginally significant association between DII Q1 and BMI
(p=0.057). A significant inverse association was observed between DII Q3-Q4 and
insulin level (p=0.006 and p=0.030, respectively). After adjusting for covariates, age,
gender, waist circumference, FPG and 25(OH)D, the model remained significant for both
Q3 and Q4 (p=0.040 and p=0.049, respectively). There was a significant association
between SBP and DII in Q4 (p=0.029). However, after adjusting the model for the
covariates the model lost significance.
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Discussion:
To our knowledge, this is the first study examining the associations between
dietary inflammatory index (DII) and biomarkers of inflammation (CRP), oxidative stress
(8-OHdG), and glycemic status [glycated hemoglobin (HbA1c) and glycated albumin
(GA%)] among individuals with type 2 diabetes and vitamin D deficiency/insufficiency.
The results of this cross-sectional analysis of data showed no statistically significant
relationship between DII, CRP, 8-OHdG, HbA1c and GA%. This confirms the findings
of Almeida et al. (38) who found no significant associations between DII score and CRP
level among adolescents from the LabMed physical activity study. Furthermore, in a
study among 2,567 postmenopausal women, Tabung et al. (39) found no significant
association between DII and CRP. However, Tabung et al. found another biomarker of
inflammation, IL-6, to be significantly associated with DII. This is not consistent with the
results of Cavicchia et al. (22) and Shivappa et al. (23) who found DII to be a significant
predictor of CRP. It may be due to the smaller sample size in the present study (n=68
compared to n=600 in the Cavicchia et al.). Furthermore, DII is a literature-derived tool
based on 1,943 articles on the effect of diet on a panel of inflammatory biomarkers (IL1β, IL-4, IL-6, IL-10, TNF-α, and CRP). It is not clear whether any of these biomarkers
of inflammation are more sensitive to DII score across various racial/ethnic groups. In
addition, the dietary intakes have been recorded with different methods across the studies.
For the example Cavicchia at al. (22) obtained the dietary intakes data for each
participant from a randomly selected 24-hour recall. This is while Almeida et al. (38)
used a semi-quantitative food frequency questionnaire validated for the Portuguese
population. It is worth noting that not all the studies used all forty-five food parameters
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included in the updated DII developed by Shivappa et al. (23). This may be due to
unavailability of some dietary information caused by the various methods of dietary data
collection. In our study, we included 34 food parameters, based on the availability of the
dietary information. Food items such as eugenol, garlic, ginger, onion, saffron, turmeric,
green/black tea, Isoflavones, pepper, thyme/oregano, and rosemary were not available
and were not included in the present study. This may be a source of variation in DII
range in across different studies; The DII range in our study was (-5.214, +3.999), while
the range for the global database developed by Shivappa et al. (23) was (-8.87, +7.98).
A significant correlation was found between DII score and HbA1c (r=0.529,
p=0.029) in the second quartile (Q2) in the present study, and the unadjusted linear
model also showed an association between DII and HbA1c. These results were
inconsistent with findings of Wouderndergh et al. (40) who did not find an association
between adopted DII and HbA1c among 1,024 Dutch participants. The present study
found a significant inverse association between DII Q3-Q4 and insulin levels (p=0.006
and p=0.030, respectively). After adjusting for covariates, age, gender, waist
circumference, FPG and 25(OH)D, the model remained significant (p=0.040 and
p=0.037). This suggests individuals with higher pro-inflammatory dietary intakes may
have lower insulin levels. This means a pro-inflammatory diet may play a role in insulin
production and release from β-cells in pancreas. Moslehi et al. (41) reported no
significant association between DII and insulin levels and insulin resistance among 2,975
Iranian adults. This may be due to the health status difference among the participants of
this study (without type 2 diabetes), compared to the present study included only
individuals with type 2 diabetes. In addition, mean age was lower (45 ± 11.7 years) in the
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study conducted by Moslehi et al. (41), compared to the present study (54.94 ± 7.93
years).
There was a significant association between SBP and DII in Q4 (p=0.029). This
may suggest more pro-inflammatory dietary patterns can lead to a higher risk of
developing blood pressure abnormalities. However, after adjusting the model for the
covariates mentioned above, the model lost significance. Consistent with our findings,
Vissers et al (42) also found pro-inflammatory diets associated with increased risk of
developing hypertension among a cohort of middle-aged Australian woman.
Conclusion:
A pro-inflammatory diet may be associated with increased risk of hypoinsulinemia and incidence of higher SBP among individuals with type 2 diabetes and
vitamin D deficiency/insufficiency. The limitations of this study were the small sample
size and the exclusion of individuals with adequate serum 25(OH)D levels to serve as a
base for comparison. Furthermore, due to unavailability of the dietary information, eleven
food parameters were not included in the DII calculations. The strengths of the study
were its innovation in studying the association between DII and biomarkers of
inflammation (CRP), oxidative stress (8-OHdG), and glycemic status (HbA1c and GA%)
among individuals with type 2 diabetes and vitamin D deficiency/insufficiency. The
results of this study may serve as a basis for future nutrition interventions to improve
anti-inflammatory intakes, developing culturally appropriate anti-inflammatory
counseling and improving the health status of individuals with type 2 diabetes.
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Table 1. Thirty-five food parameters obtained from the food frequency questionnaire to
calculate the dietary inflammatory index
Food parameter

Overall inflammatory effect score

Alcohol (g)
-0.278
Vitamin B12 (µg)
0.106
Vitamin B6 (mg)
-0.365
β-Caroten (µg)
-0.584
Caffeine (g)
-0.110
Carbohydrate (g)
0.097
Cholesterol (mg)
0.110
Energy (kcal)
0.180
Total fat (g)
0.298
Fibre (g)
-0.663
Folic acid (µg)
-0.190
Iron (mg)
0.032
Magnesium (mg)
-0.484
MUFA (g)
-0.009
Niacin (mg)
-0.246
n-3 fatty acids (g)
-0.436
n-6 fatty acids (g)
-0.159
Protein (g)
0.021
PUFA (g)
-0.337
Riboflavin (mg)
-0.068
Saturated fat (g)
0.373
Selenium (µg)
-0.191
Thiamin (mg)
-0.098
Trans fat (g)
0.229
Vitamin A (RE)*
-0.401
Vitamin C (mg)
-0.424
Vitamin D (µg)
-0.446
Vitamin E (mg)
-0.419
Zinc (mg)
-0.313
Flavan-3-ol (mg)
-0.415
Flavones (mg)
-0.616
Flavonols (mg)
-0.467
Flavonones (mg)
-0.250
Anthocyanidins (mg)
-0.131
Eugenol, garlic, ginger, onion, saffron, turmeric, green/black tea, Isoflavones, pepper,
thyme/oregano, and rosemary were not included in the present study. *RE = retinol
equivalent.
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Table 2. Baseline Characteristics
Characteristics

Total
(N= 68)
Mean ± SE

Q1*
(n=17)
Mean ± SE

Q2*
(n=17)
Mean ± SE

Q3*
(n=17)
Mean ± SE

Q4*
(n=17)
Mean ± SE

Age (years)
Gender (%
female)
BMI (kg/m²)
SBP

54.94 ± 7.93
60.3

54.47 ± 6.57
58.8

56 ± 9.93
58.8

54.06 ± 6.47
76.5

55.24 ± 8.81
47.1

33.70 ± 6.59
133.706 ±
22.59
84.97 ± 12.57

32.65 ± 4.08
136.56 ±
21.25
85.47 ± 9.26

32.86 ± 5.91
135.59 ±
18.92
85.29 ± 10.63

37.14 ± 8.72
130.65 ±
25.62
85.94 ± 17.02

22.34 ± 6.68

22.78 ± 6.34

22.40 ± 5.93

21.79 ± 6.41

32.15 ± 6.10
132.03 ±
25.18
83.18 ±
12.99
22.38 ± 8.31

7.91 ± 10.60
8068.94 ±
2158.13
5.51 ± 3.28
8.35 ± 2.28
184.26 ±
79.02
12.64 ± 11.38

7.87 ± 10.87
7787.73 ±
2010.92
5.29 ± 2.84
8.14 ± 2.01
183.82 ±
71.65
11.58 ± 8.71

7.92 ± 12.56
8174.39 ±
3018.67
6.03 ± 4.30
7.87 ± 1.95
173.65 ±
70.92
17.46 ± 17.05

10.43 ± 12.50
7572.12 ±
1835.72
4.49 ± 1.80
9.13 ± 2.62
203.12 ±
99.19
11.46 ± 6.68

5.43 ± 5.01
8741.50 ±
1462.46
6.24 ± 3.65
8.26 ± 2.47
176.47 ±
74.73
10.08 ± 4.95

DBP
25(OH)D
(ng/mL)
CRP
8-OHdG
(pg/mL)
GA%
HbA1c
FPG (mg/dL)
Insulin
(mIU/L)
PTH (pg/mL)

39.52 ±
33.90 ± 16.40 34.52 ± 17.76 42.87 ± 18.19
46.49 ±
18.139
17.47
*Quartiles; Q1 (-5.214, -1.827), Q2 (-1.826, -0.653), Q3 (-0.652, +1.138), Q4 (+1.138, +3.999).
BMI = Body mass index. SBP = systolic blood pressure. DBP = diastolic blood pressure. CRP =
C-reactive protein. GA% = Glycated albumin/albumin *100. FPG = fasting plasma glucose, PTH
= parathyroid hormone.
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Table 3. Association between Dietary Inflammatory Index and covariates within each
quartile
Parameter*

Unadjusted

Adjusted

β

SE

Q1

0.340

1.418

1.398

0.182

Q2

0.088

2.104

0.342

0.737

Q3

0.636

0.703

3.188

0.006†

-0.594 0.921 -2.362

0.040†

Q4

-0.526

0.505 -2.398 0.030†

-0.619 0.635 -2.246

0.049†

Q1

0.447

3.29

1.937

0.072

Q2

0.100

2.09

0.388

0.703

Q3

-0.400

3.32

-1.692

0.111

Q4

0.528

2.57

2.408

0.029†

T

P-value

β

SE

T

P-value

Insulin (mIU/L)

SBP (mmHg)

0.486

0.23

1.815

0.10

*Other covariates in the multiple regression model were age, gender, waist circumference
and fasting plasma glucose and 25(OH)D. † Statistically significant. P < 0.05 is
considered significant.
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CHAPTER III: EFFECT OF VITAMIN D3 SUPPLEMENTATION ON
DNA/RNA OXIDATIVE STRESS IN ADULTS WITH TYPE 2 DIABETES
Introduction
Oxidative stress is caused by an imbalance between oxygen metabolites
production and ability of the endogenous and exogenous antioxidant networks to
neutralize them (1). Reactive oxygen species (ROS), such as superoxide anion (O2−),
hydrogen peroxide (H2O2), hydroxyl radical (OH°) and peroxynitrite (OONO−), have one
or more unpaired electrons and are highly reactive (2). ROS may attack other molecules
to take an electron from them and stabilize (3). They can damage proteins, lipids and
DNA. These oxidized biomolecules may trigger further oxidizing chain reactions that
may result in production of new free radicals (3-4). Oxidative stress plays a pivotal role
in systemic inflammation, type 2 diabetes development and its related complications (5).
Although ROS production is one of the primary defense mechanisms, increased ROS
production may result in impaired oxidative balance which leads to activation of nuclear
factor κB (NF-κB). NF-κB plays a critical regulatory role in immunity and inflammatory
responses (4). NF-κB regulates the expression of a variety of genes such as growth
factors and pro-inflammatory cytokines and enhances a signaling cascade which leads to
sustained production of ROS and causing low grade inflammation (6). Continued
production of pro-inflammatory cytokines results in an acute phase response by the innate
immunity and lead to pancreatic β cell apoptosis and dysfunction. This process
diminishes the ability of the pancreas to produce and release insulin and thus causes type
2 diabetes.
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ROS induced oxidation of guanine residues of DNA can damage the DNA strands
and produce 8-hydroxydeoxyguanosine (8-OHdG) (7). Several studies had shown
increased 8-OHdG levels among individuals with type 2 diabetes (8-9). It has been
suggested that 8-OHdG may be a predictive biomarker for early detection of lifestyle
related health conditions, such as type 2 diabetes, at population level (10).
Nutrition plays a vital role in maintaining the oxidative balance. The direct effect
of nutrition is via providing dietary antioxidants to the exogenous antioxidant network. In
addition, nutrition affects the oxidative balance indirectly by providing energy to the
endogenous enzymatic antioxidant system and therefore enhances its function (3). On the
other hand, over-nutrition and physical inactivity are stressors that contribute to ROS
production by inducing hyperglycemia and increased glucose accumulation in the muscle
tissue, adipose tissue and pancreatic cells (2). ROS formed by autoxidation of glucose in
the muscle tissue, adipose tissue, and pancreatic cells may non-enzymatically react with
proteins and result in further production of ROS (11). These pathogenic effects can lead
to development of insulin resistance, Beta cell dysfunction and glucose intolerance and
thus result in type 2 diabetogenesis. In animal models, ROS impaired insulin synthesis
via suppression of insulin gene expression in pancreatic Beta cells (6). Antioxidant
treatment in diabetic rats resulted in improved insulin secretion (6). It has been suggested
that decreasing oxidative stress may have beneficial effects on the health of individuals
with type 2 diabetes (2), and that antioxidant therapy may be a potential solution to
reduce type 2 diabetes-related complications (6).
The antioxidant properties of vitamin D3 in human under diabetes conditions are
not clear. One potential anti-oxidative action of vitamin D may be via suppression of
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intracellular NF-κB which result in down-regulation of pro-inflammatory cytokines (12).
Diminished pro-inflammatory cytokine levels prevent B cell apoptosis and improves B
cell survival (5). In addition, 1,25(OH)2D3 known as the active form of vitamin D3,
activates the expression of anti-inflammatory cytokines such as IL-4, IL-10 and TGF-B1
(13). Deluca et al. (13) suggested that vitamin D may have an immunosuppressive
property due to its effect on regulation of pro-inflammatory and anti-inflammatory
cytokines. Vitamin D supplementation could decrease oxidative stress in human
colorectal mucosa as measured by 8-OHdG (14). Furthermore, 1,25(OH)2D3 is proved to
have protective properties against UV-induced oxidative DNA damage in skin cells (15).
Sun exposure have been shown to be a critical factor in maintaining serum
vitamin D level in human (16). It has been reported that exposed skin areas’ color, such
as forearm skin color, are significantly associated with serum 25(OH)D3 and that forearm
skin color may be an accurate predictor of serum vitamin D (16). Several studies showed
that lighter skin color is associated with higher serum 25(OH)D3 levels (16-19).
Considering the antioxidant properties of vitamin D and the role of sun exposure in
maintaining the serum vitamin D level, further investigations are required to assess the
association between skin color and oxidative stress under hypovitaminosis D and diabetes
conditions.
Effectiveness of vitamin D3 supplementation on DNA/RNA oxidative stress
under type 2 diabetes condition in human is not clear. Trials among human subjects are
needed to investigate and quantify the potential beneficial impact of vitamin D3
supplementation at different dosages among individuals with vitamin D deficiency.
Therefore, the aim of this study was to investigate the effect of 4000 IU and 6000 IU
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daily supplementation of vitamin D3 for 3 and 6 months on a biomarker of DNA/RNA
oxidative stress, 8-OHdG, in individuals with type 2 diabetes and serum vitamin D
[25(OH)D3] insufficiency or deficiency. In addition, we investigated the relationship
between skin exposure score, as a measure of sun exposure, and oxidative stress in
individuals with type 2 diabetes and 25(OH)D3 deficiency or insufficiency. We
hypothesized that daily supplementation with 4000 and 6000 IU of vitamin D3 for 6
months will decrease serum 8-OHdG level in individuals with type 2 diabetes and
vitamin D insufficiency or deficiency, compared to baseline. To our knowledge, this is
the first study investigating the effects of vitamin D3 supplementation on 8-OHdG among
human subjects with type 2 diabetes. Furthermore, we hypothesized individuals with
lighter forearm skin color will have lower 8-OHdG levels compared to those with darker
forearm skin color, at baseline, and that individuals with higher skin exposure scores, as
measured by the difference between exposed and unexposed skin colors, will have lower
8-OHdG levels.
Materials and methods:
This clinical trial, assessed the effect of daily supplementation with 4000 and
6000 IU of vitamin D3 over six months on biomarker of DNA/RNA oxidative stress
among adults with type 2 diabetes living in South Florida. The parent study was
conducted by Huffman et al. (20) assessing the effect of vitamin D3 supplementation on
cardiovascular disease biomarkers. In the present study, serum samples collected at
baseline, 3 months and 6 months stored at -80˚ʿ were used to measure DNA/RNA
oxidative stress level (8-OHdG).
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Study participants were recruited from 2 sources:
- From community areas by distributing flyers including the purpose of the study,
inclusion and exclusion criteria, and the investigators information.
- From 2 clinics: Borinquen Health care center and Clinical Care Medical
center. Weekly visits were conducted to recruit study participants.
Interested individuals called the investigators and expressed their willingness to
participate in the study and were asked to answer a few pre-screening questions.
Qualified individuals were invited for screening at the Human Nutrition Laboratory,
Florida International University. After signing the informed consent form, fasting blood
samples were collected and screening questionnaires were administered to evaluate
whether the inclusion criteria were met (20).
Inclusion criteria was being 30-70 years old, being African-American or Hispanic,
having Type 2 diabetes, and being vitamin D insufficient [25(OH)D3 < 30 ng/mL].
Exclusion criteria was being pregnant or lactating, taking vitamin D supplements,
injecting insulin, suffering from thyroid, hepatic and/or renal complications, suffering
from HIV, or cancer. The duration of the intervention was 6 months and participants were
contacted at four-time points:
Time zero (T0): Screening: During screening the eligibility of the participants to
enroll in the study was assessed based on the inclusion and exclusion criteria. Participants
signed an informed consent form before the data collection. Fasting blood was collected
for screening of vitamin D status.
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Time one (T1): Baseline: All participants who met the inclusion criteria
participated in the study. Blood collection, anthropometric measurements, skin color
measurements, and a socio-demographic questionnaire were administered at baseline and
vitamin D supplements (pills) were provided to the participants (4000 and 6000 IU/pill).
Time two (T2): Blood collection, anthropometric measurements, and skin color
measurements were administered after 3 months of supplementation with 4000 IU or
6000 IU vitamin D3 pills. Additional vitamin D3 pills were provided to the participants.
Time three (T3): Blood collection, anthropometric measurements, and skin color
measurements were administered after 6 months of supplementation. Study was
terminated at this point.
Table 1. Parent Study Timeline
Time

Assessments

Screening (T0)

Informed consent form signing, fasting blood collection, screening
questionnaire

Baseline (T1)

Fasting blood collection, sociodemographic questionnaire, food frequency
questionnaire, skin color measurement, anthropometric measurement

3 months (T2)

Pill count, fasting blood collection, skin color measurement

6 months (T3)

Pill count, fasting blood collection, skin color measurement

Measurements of variables:
a. Socio-demographic questionnaire
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A socio-demographic questionnaire was used to collect information about age,
gender, race/ethnicity, years living in the United States and years having type 2 diabetes.
b. Anthropometric measurements
Height and weight measurements were taken by using a SECA balance scale
(SECA Corp, Columbia, MD), to the nearest 0.5 cm and 0.1 kg, respectively. Waist
circumference was measured by using a measuring tape to the nearest 0.1 cm. Systolic
and diastolic blood pressure were measured in a sitting position by using an automated
arm-cuff monitor. All measurements were done twice and the average of two readings
was considered in the analysis.
c. Skin color measurement
Reflectance colorimetry method was used to determine skin color as an objective
measure of skin sun exposure (IMS Smart Probe 400, Millford CT, USA) (20). This
instrument uses the International Commission on Illumination Scale and ranges the skin
color from 0 (black) to 100 (white). The measurement sites included 3 areas: wrist of the
right hand as the most exposed area to sun, inside of the right upper arm and the waist as
the least exposed areas to the sun (20). Each measurement was conducted 2 times and the
average was considered in the proposed study analysis. This tool is validated by several
studies (16, 20-21). Skin sun exposure level was determined by calculating the difference
between the wrist of the right-hand skin color (the most exposed) and the inside of the
right upper arm (the least exposed).
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d. Food frequency questionnaire
A validated short vitamin D and calcium questionnaire developed by Blalock (22)
was used to assess the dietary calcium and vitamin D intakes. The modified questionnaire
added pizza to the 22 existing foods and beverages and asked for serving size and
frequency of consumption of each food (16). This tool is validated by several studies (16,
20, 22).
e. Physical activity
Physical activity was measured using the Modifiable Activity Questionnaire
(MAQ), which has been validated for individuals with type 2 diabetes (23-24). This
questionnaire by Kriska et al. (25) measures the levels of leisure and occupational
physical activity for over the past year in sum of hours per week. After collecting this
information, the sum of hours per week were multiplied by the estimated metabolic rate
to calculate metabolic equivalents (METs)/hours per week.
f. Perceived stress
Perceived stress level was measured by using Perceived Stress Scale (PSS-10)
(26-27). The response categories in this questionnaire were ranged from ‘never’ = 0,
‘almost never’ = 1, ‘sometimes’ = 2, ‘fairly often’ = 3, and ‘very often’ = 4. The total
score outcome ranges from 0-40 which reflects perceived stress level. This questionnaire
has been validated among individuals from different racial and ethnic groups, with and
without type 2 diabetes (28).
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g. Blood collection and analysis
Fasting venous blood was collected by a certified phlebotomist (15 mL). After
coagulation of blood samples in serum separator tubes for 30-45 minutes, samples were
centrifuged at 2500 RPM for 30 minutes to obtain the serum. Fasting plasma glucose
concentration was measured by hexokinase enzymatic method, glycated hemoglobin A1c
(HbA1c) was measured by using DCA2000 + system (BAYER Corporation, Diagnostics
Division, N.Y) and 25(OH)D3 concentrations were measured by using an enzymatic
immunoassay kit (Immunodiagnostic Systems Scottsdale, AZ) (16).
h. Oxidative stress
Oxidative stress biomarker, 8-hydroxyguanosine (8-OHdG), was assessed using a
human DNA/RNA oxidative damage competitive enzyme-linked immunosorbent assay
(Cayman Chemical, Ann Arbor, MI, item No 589320); this immunoassay measures the
DNA/RNA damage by detecting 8-hydroxy-2`-deoxyguanosine and 8-hydroxyguanosine
from DNA and RNA, respectively. In addition, it detects 8-hydroxyguanine from both
DNA and RNA which provides more accurate information about biologic products of
oxidative stress, compared to other available assays which mostly detect only one of the
three biomarkers mentioned (29). As recommended by the assay protocol, initially 15
serum samples were diluted with the assay buffer within the range of 1:25 - 1:100. After
analyzing the results, dilution 1:50 was used for this study. Participant`s serum samples
were defrosted and diluted with the assay buffer to 1:50. Assay standards were prepared
in 8 test tubes by serially diluting the bulk standard from tube 1 to tube 8. Coated plates
with goat polyclonal anti-mouse IgG were prepared with standards and serum samples
based the assay protocol. Each standard and sample were run in duplicates. After addition
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of DNA/RNA oxidative damage assay monoclonal antibody, plated were covered and
incubated for 18 hours at 4°c. After completion of the incubation, plates were washed 5
times with the assay wash buffer and were developed in dark with developing reagent for
100 minutes on an orbital shaker. Each plate was read at 405 wavelengths using a plate
reader located at Huffman Nutrition Laboratory at Florida International University. Data
was plotted and analyzed using a pre-configured analysis tool for Cayman DNA/RNA
oxidative damage ELISA kit.
Statistical analysis:
The IBM statistical package for the social sciences (SPSS) version 20 (Chicago,
IL, USA) was used for performing the statistical analysis. Descriptive statistics were
conducted for baseline characteristics. Numerical normally distributed data and
categorical data were compared using paired t-test and Chi-Squared test, respectively.
The main outcome was serum 8-OHdG. Gender and time were input as categorical and
the rest of variables were input as continuous in the analysis. G*Power 3.0.10 software
was used for post-hoc power analysis. Mixed model was used to compare 4000 IU and
6000 IU treatment groups. In this model, oxidative stress (8-OHdG) was the dependent
variable and supplementation time was the independent variable. Covariates were age,
gender, BMI, insulin level, HbA1c level, years with type 2 diabetes, perceived stress
level, physical activity, and skin exposure score. Factors included gender and treatment
groups. To compare the changes from baseline, three months and six months, Bonferroni
multiple comparison test was used at the statistical significance of P-value <0.05.
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Results
Out of 92 individuals who were screened at baseline, 77 met the inclusion criteria
and participated in the interventions. Two subjects were excluded due to missing values
for sun exposure. Sixty-eight participants completed the study, females (n=41) and males
(n=27), and were included in the present study`s analysis. Descriptive characteristics are
featured in Table 2. Mean age was 54.94 ± 7.93 years. Mean years with type 2 diabetes
was 6.44 ± 5.23 years. Oxidative stress (8-OHdG) was measured at baseline, after 3
months and after 6 months. The unadjusted mean ± SD for 8-OHdG levels at baseline,
after 3 months and after 6 months were 8068.94 ± 2158.13 pg/mL, 9462.22 ± 2403.89
pg/mL, and 7412.69 ± 2031.68 pg/mL, respectively (Figure 1). Paired t-test comparisons
showed a statistically significant change in 8-OHdG level between baseline and 3 months
(P<0.001), 3 months and 6 months (P<0.001), and baseline and 6 months (P=0.013)
(Figure 3). The unadjusted mean ± SD for serum 25(OH)D3 at baseline, after 3 months
and after 6 months were 22.34 ± 6.67 ng/mL, 40.77 ± 13.63 ng/mL, and 40.41 ± 14.50
ng/mL, respectively (Figure 2). Paired t-test comparisons showed a statistically
significant change in 25OHD3 level between baseline and 3 months (P<0.001), and
baseline and 6 months (P<0.001). There was no statistically significant difference in
serum 25OHD3 between 3 months and 6 months of supplementations (Figure 3).
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Figure 1. Mean DNA/RNA oxidative stress level (8-OHdG) at baseline, after 3 months,
and after 6 months of supplementation with vitamin D3. Serum 8-OHdG level
significantly increased after 3 months of supplementation with vitamin D3 and then
significantly decreased after from 3 months to 6 months after supplementation with
vitamin D3. * Statistically significance from baseline. † Statistically significant from 3
months. P< 0.05 is considered significant.
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Figure 2. Mean serum vitamin D3 level [25(OH)D3] at baseline, after 3 months, and after
3 months of supplementation with vitamin D3. * Statistically significance from baseline.
P< 0.05 is considered significant.
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Figure 3. Mean DNA/RNA oxidative stress level (8-OHdG) and mean serum 25(OH)D3
at baseline, after 3 months, and after 6 months of supplementation with vitamin D3. *
Statistically significance from baseline. † Statistically significant from 3 months. P< 0.05
is considered significant.
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There were 46 participants in the 4000 IU/day intervention group and 22
participants in the 6000 IU intervention group. The unadjusted mixed model showed no
significant differences between the 4000 IU and 6000 IU groups regarding the oxidative
stress level and the interactions between time and treatment were not significant. The
model showed a statistically significant increase in 8-OHdG level between baseline and 3
months (P<0.001), but a significant decrease between 3 months and 6 months (P<0.001),
and baseline and 6 months (P=0.016) (Table 3).
After adjusting for age, gender, BMI, insulin level, HbA1c level, years with type
2 diabetes, perceived stress, physical activity, and skin sun exposure level, the model
remained statistically significant; Pairwise comparisons showed significant changes in 8OHdG level between baseline and 3 months (P<0.001), between 3 months and 6 months
(P<0.001), and between baseline and 6 months (P=0.020) (Table 4).
There were no significant correlations between exposed and unexposed skin color
(forearm, upper-arm, and stomach) and the oxidative stress level at baseline, 3 months
and 6 months. In addition, no statistically significant relations were found between skin
sun exposure (difference between the exposed and unexposed skin color) and oxidative
stress level at baseline, 3 months and 6 months. No adverse events associated with
supplementation were reported by any of the study arms during the 6-month period of
participation.
Discussion
To our knowledge this was the first interventional study among human subjects
with type 2 diabetes investigated the effect of long-term supplementation of different
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dosages of vitamin D3 on the biomarker of DNA/RNA oxidative stress, 8-OHdG. The
results of the present study suggest daily supplementation with vitamin D3, both 4000 IU
and 6000 IU, for 6 months may improve the DNA/RNA oxidative stress status among a
group of individuals with type 2 diabetes and vitamin D deficiency/insufficiency. The
improvement remained significant after adjusting for age, gender, BMI, insulin level,
hemoglobin A1C level, years with type 2 diabetes, perceived stress level, physical
activity, and skin exposure score.
In contrast with our study, Nikooyeh et al. (30) reported that daily intake of
vitamin D fortified yogurt drink for 12 weeks decreased biomarkers of oxidative stress
among 90 of individuals with type 2 diabetes. Different from our study, the daily vitamin
D3 supplementation for this study was significantly lower (500 IU vs 4000/6000 IU), and
the baseline serum vitamin D level among their participants was 44.8 ± 28.7 ng/mL,
which was above the sufficient level of 30 ng/mL (30).
The dissimilarities in design between the two studies may explain why we could
not detect improvement in oxidative stress status for the first 3 months of the study. As
evidenced by our results, decrease in oxidative stress level occurred only after study
subjects reached the sufficient serum 25(OH)D3 level (>30 ng/mL). Therefore, although
oxidative stress was increasing from baseline to 3 months, we observed a significant
decrease in oxidative stress between 3 months and 6 months with daily supplementation
of vitamin D3. In fact, the mean 8-OHdG at 6 months was significantly lower than the
mean 8-OHdG at both baseline [8068.94 ± 2158.13 pg/mL to 7412.69 ± 2031.68 pg/mL
(P=0.013)] and 3 months [9462.22 ± 2403.89 pg/mL to 7412.69 ± 2031.68 pg/mL
(P<0.001)]. This may suggest the beneficial effects of vitamin D3 supplementation on
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oxidative stress under diabetes conditions may be observed after the replenishment of
serum vitamin D. Therefore, our findings suggest that longer duration of vitamin D3
supplementation is needed among individuals with type 2 diabetes and vitamin D
deficiency/insufficiency.
The outcome of another longitudinal study among 103 patients with type 2
diabetes and vitamin D deficiency, which aimed to evaluate the effect of vitamin D3
supplementation on oxidative stress (31) showed weekly supplementation with 60,000 IU
of vitamin D3 for 8 weeks could improve oxidative stress level among individuals with
type 2 diabetes and vitamin D deficiency. Participants consumed 4 sachets of
cholecalciferol with 120 ml of milk every week for 4 weeks. The mean serum 25(OH)D
at baseline was 14.6 ng/mL and was significantly increased to 42.33 ng/mL (P<0.001)
after the 8 weeks of intervention with this larger doses. Although both studies are in
agreement that vitamin D3 supplementation significantly improves the oxidative status
among individuals with type 2 diabetes and vitamin D deficiency, in our study we could
find improvement in oxidative stress status only after 6 months of intervention. This may
be due to significantly higher dosage of supplementation (equivalent to 8571/day IU) in
the Anansabaskar et al. (31) compared with our daily supplementation of 4000 IU or
6000 IU of vitamin D in our study.
Several other studies among human subjects also revealed that vitamin D
supplementation may have beneficial effects on oxidative stress status (32, 33). In a
randomized double-blind placebo-controlled trial among 104 female subjects with
vitamin D deficiency and polycystic ovary syndrome, weekly supplementation with
50,000 IU of vitamin D for 8 weeks improved the biomarkers of oxidative stress (32). In
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another study among 53 adults with non-alcoholic fatty liver disease, Sharifi et al. (33)
reported oral supplementation with 50,000 IU of vitamin D3 every 14 days for 4 months
improved serum 25(OH)D3 status as well as biomarkers of oxidative stress. The present
study did not find a significant association between serum 25(OH)D3 and 8OHdG. This
may be due to small sample size of the current study and low power.
Animal studies suggest an antioxidant role for vitamin D. Konko et al. (34)
showed that vitamin D analog could reduce oxidative stress in non-obese type 2 diabetic
rats as measured by 8-OHdG. It has been suggested that vitamin D induced decrease in
oxidative stress determines the vasoprotective properties of vitamin D. Administration of
paricalcitol, a vitamin D receptor antagonist, could improve pancreatic oxidative stress in
type 2 diabetic rats (35). It has been concluded that vitamin D may protect B cells from
damages caused by ROS and therefore may prevent B cell dysfunction and apoptosis
(35). In rats with alloxan-induced diabetes, vitamin D administration could increase the
antioxidant activities of enzymes and decrease oxidative stress, especially in the
pancreatic tissue (36). This study suggested a therapeutic role for vitamin D in diabetes
condition.
Conclusion
The results of the present study implied daily oral supplementation with higher
doses of vitamin D, 4000 IU and 6000 IU/day, for 6 months may improve oxidative stress
status among a group of individuals with type 2 diabetes and vitamin D
deficiency/insufficiency. It also showed that there were no significant differences
between the lower and higher doses on the effect on oxidative stress. Neither arm
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reported adverse effects of supplementation during the six months of participation,
therefore, both doses were considered safe. Furthermore, 8-OHdG may be a predictive
biomarker of DNA/RNA damage among individuals with type 2 diabetes. The limitations
of this study included lack of a control group, small samples size, and exclusion of
participants with sufficient serum vitamin D levels. The strengths of the study were the
ability to compare 2 different dosages of vitamin D3 supplementation, the longevity of
study and measurement of sun exposure. We did not find significant changes in sun
exposure during the 6-month period of this study. Further interventional studies among
human subjects with larger sample sizes and longer observation timelines are required to
confirm the antioxidants effects of vitamin D on RNA/DNA oxidative stress.
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Table 2. Participants characteristics at baseline (N = 68)
Variable

Mean ± SD
N= 68
54.94 ± 7.93

Age (years)
Gender n (%)
Female
Male
Dosage n (%)
4000 IU
6000 IU
BMI (Kg/m2)
Years with T2DM
Forearm skin color
Upper-arm skin color
Skin exposure score
Physical activity (METs/hour/week)

41 (60)
27 (40)
46 (68)
22 (32)
33.7 ± 6.59
6.44 ± 5.23
55.29 ± 7.49
59.87 ± 8.66
4.58 ± 4.27
14.65 ± 25.68

Data are % or mean ± standard deviation (SD). IU = International Unit. BMI = Body
mass index. Sun exposure is defined by calculating the difference between quantitative
measures of forearm skin color and upper-arm
skin color. METs = Metabolic equivalents.
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Table 3. Mixed model comparisons of repeated measures at baseline, after 3 months and
after 6 months without adjustment for covariates.
Variable
8-OHdG (pg/mL)
Baseline
3 months
6 months
25(OH)D (ng/mL)
Baseline
3 months
6 months

Mean ± SE
(N= 68)
8014.86 ± 277.19
9649.95 ± 302.467
7338.26 ± 260.12

22.41 ± 0.87
42.35 ± 1.67
41.14± 1.87

P-value

*0.001
*0.016, †0.001

*0.001
*0.001

Data represented by mean ± standard error. * Statistically significance from baseline.
† Statistically significant from 3 months. P-values are from multiple comparisons with
Bonferroni correction. P<0.05 is considered significant. Time and dosage interactions
were not significant for any of the variables.
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Table 4. Mixed model comparisons of repeated measures at baseline, after 3 months and
after 6 months with adjustment for covariates (N = 68).
Mean ± SD
(N= 68)
8-OHdG (pg/mL)
Baseline
3 months
6 months

8064.905 ± 266.12
9677.06 ± 278.45
7395.60 ± 253.64

*P-value

*0.001
*0.020, †0.001

Data represented by mean ± standard error. * Statistically significance from baseline.
† Statistically significant from 3 months. P-values are from multiple comparisons with
Bonferroni correction. P<0.05 is considered significant. Time and dosage interactions
were not significant for 8-OHdG. Mixed model analysis was adjusted for age, gender,
BMI, insulin level, HbA1C level, years with type 2 diabetes, perceived stress level,
physical activity, and skin exposure score.
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CHAPTER IV: EFFECT OF VITAMIN D3 SUPPLEMENTATION ON
GLYCATED ALBUMIN IN ADULTS WITH TYPE 2 DIABETES
Introduction
Diabetes mellitus is ranked as the seventh leading cause of death in the United
States (1). According to the 2014 National Diabetes Statistics Report by the Centers for
Disease Control and Prevention (CDC), over 29 million individuals (9.3% of the U.S
population) were diagnosed with diabetes while more than 8 million cases remained
undiagnosed (2). Type 2 diabetes accounts for 90-95% of all diagnosed diabetes cases
among adults.
Type 2 diabetes and early glycation products
Persistent hyperglycemia leads to non-enzymatic glycation of proteins, known as
Maillard reaction. In this reversible process, the carbonyl group of reducing sugars, such
as glucose, binds to the amino group on lysine residues of proteins, such as hemoglobin,
and form early glycation products known as Schiff-bases and Amadori adducts (3). Early
glycation leads to formation of intermediate glycation products (IGPs) such as glycated
hemoglobin (HbA1c) and glycated albumin (GA). Continuous elevation in IGP levels can
lead to their irreversible rearrangement to stable advanced glycation end products (AGEs)
(3-4). AGEs accumulation is a measure of carbonyl, metabolic and oxidative stress and
serve as a long term metabolic memory, rather than short term glycemic control. In
contrast, IGPs are better indicators of glycemic control (4). Amadori adducts, the major
form of IGPs, have 2-3 times higher concentrations of glycated products than AGEs (5).
HbA1c is currently an established gold standard Amadori adduct, reflecting the glycemic
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control over the period of 8-12 weeks. In addition, HbA1c is associated with the risk of
chronic diabetes related complications such as neuropathy, nephropathy, retinopathy and
coronary artery disease (5-6). HbA1c level, however, can be affected by several factors
such as red blood cells turnover, uremia, erythropoietin treatment, blood transfusion,
anemia, renal malfunction, and iron-deficiency (5). Based on the twin studies by Sneider
et al. (7), HbA1c is strongly inherited and influenced by genetics. Furthermore, HbA1c
reflects on the glycemic control inside the RBCs while serum protein glycation reflects
glycemic control in the extracellular space (8).
Albumin is the most abundant protein in plasma and makes more than 50% of
plasma proteins (9). With a half-life of 14-21 days, albumin is known as the main
extracellular antioxidant and plays a fundamental role in maintaining oxidative balance
(10). Furthermore, albumin has anti-inflammatory and anti-thrombotic properties and
plays a crucial role in transportation of nutrients, metabolites, hormones and drugs while
maintaining the osmotic pressure (5). As a lysine rich protein with 59 lysine residues,
albumin is widely involved in extracellular Maillard reactions under hyperglycemic
conditions (5). Non-enzymatic glycation of albumin happens 10 times faster and 9 times
more than non-enzymatic glycation of hemoglobin in-vivo (11). It is suggested that
glycated albumin (GA) may be a more accurate indicator of short term glycemic control
among individuals with type 1 and type 2 diabetes (12). GA have been linked to diabetes
induced complications including nephropathy, neuropathy and arteriosclerosis (9).
Although as compared to hemoglobin, serum albumin is less affected by RBC turnover,
erythropoietin treatment, blood transfusion, anemia, and iron-deficiency; albumin
turnover, hepatic cirrhosis and renal malfunction can enhance serum albumin level. It is

71

suggested GA/HbA1c ratio may be a better index of glycemic control among individuals
with diabetes (12).
Fructosamine is the measure of a combination of circulating glycated proteins,
such as glyco-lipoproteins and glyco-globlulins (13-14). Knowing that albumin is the
most abundant protein in serum, fructosamine is predominately reflecting GA, however,
GA% may provide a more accurate and efficient measure of extracellular glycation status
over 2-3 weeks (14). Furthermore, in case of abnormal albumin levels, fructosamine
values must be adjusted to albumin levels (14).
Oxidative Stress, Inflammation and Glycated Albumin
Albumin structure and antioxidant function is greatly suppressed by the Maillard
reaction. Amadori GA is in fact a stimulant for oxidative stress by producing oxygen free
radicals and lipid peroxides. Non-enzymatic glycation of albumin also suppresses its
nutrient/metabolite/drug binding affinity and diminishes its transportation ability (10). In
macrophage RAW 246.7 cells (a commercial murine cell-line), GA induced oxidative
stress activated extracellular signal-regulated kinase (ERK), influenced TGF-β1
production and activated NF-κB which plays a critical regulatory role in immunity and
inflammatory responses (15). In diabetic human endothelial cells, GA increased oxidative
stress and Reactive Oxygen Species (ROS) production by up-regulating nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase (16). This may help to understand the
role of Amadori-adducts in pathogenesis of diabetes-induced vascular complications.
Exposure of diabetic mice adipocytes to GA resulted in increased oxidative stress,
accumulation of ROS in these cells and oxidation of proteins inside them (17). GA-
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derived glycation end products (AGEs) may lead to adipocytes dysfunction and insulin
resistance in adipose tissue.
Type 2 diabetes and Vitamin D
It has been shown that both, vitamin D deficiency and type 2 diabetes, have
several risk factors in common: aging, being overweight, having a sedentary lifestyle, and
being African-American or Hispanic (18). In addition, seasonal variations have been
observed for both serum vitamin D [25(OH)D3] levels and insulin concentrations
suggesting a potential relationship between serum 25(OH)D3 and development of type 2
diabetes (19-21). Vitamin D directly affects insulin sensitivity, Beta cell function, insulin
secretion and hence mediates glucose homeostasis (18). Several studies reported an
association between lower serum vitamin D levels and increased risk of developing type
2 diabetes (22-24). In addition, a high prevalence of hypovitaminosis D has been
observed among individuals diagnosed with type 2 diabetes, compared to individuals
without type 2 diabetes (25). Beside its effect on Beta cell function and insulin
sensitivity, vitamin D also regulates calcium homeostasis which plays an important role
in regulating insulin secretion (26).
An extensive review with a meta-analyses, proposed that the direct role of vitamin
D on glucose homeostasis is mediated via binding of its metabolically active form,
1,25(OH)2D3, to the vitamin D receptors (VDR) in pancreatic Β-cells, activation of
25(OH)D3 to 1,25(OH)2D3 by the enzyme 1-α-hydroxylase (expressed in B-cells) within
B-cells, stimulating the insulin receptor gene transcription, enhancing the expression of
insulin receptor and hence affecting the insulin-mediated glucose transport (20). VDRs

73

also exist in skeletal muscle and adipose tissues which are insulin targets and are
responsible for peripheral insulin sensitivity. VDR expression in human skeletal muscle
tissue, which declines with age, stimulates regulation of protein synthesis and results in
diminished insulin sensitivity among older adults (27). In addition, animal studies
showed impaired insulin secretion in mice with inactive VDRs (28).
The indirect role of vitamin D in glucose homeostasis is determined by its effect
on regulation of extracellular calcium and calcium flux in the pancreatic B-cells (20).
Imbalance between the extracellular and intracellular calcium pools influences the ability
of B-cells to release insulin. Serum vitamin D concentration is inversely associated with
Parathyroid hormone (PTH) level, which regulates intracellular calcium (29). In animal
and in-vitro study, hypovitaminosis D was found to cause augmented PTH levels, which
resulted in elevated intracellular calcium levels (30). In adipose tissue (an insulin target
tissue), sustained augmentation in cytosolic calcium level was associated with increased
insulin resistance (30). The insulin mediated glucose uptake was decreased by 30%
among PTH injected rats (30). This could be due to increased phosphorylation of GLUT4 (an insulin-regulated glucose transporter in adipose and muscle tissue) in the presence
of elevated cytosolic calcium levels. Cross-sectional studies reported an inverse relation
between serum vitamin D level and insulin sensitivity (31-33). In addition, vitamin D and
calcium supplementation attenuated insulin resistance among non-diabetic older adults
with impaired fasting plasma glucose (FPG) (34).
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Vitamin D and Glycated Albumin
The relationship between vitamin D and GA is yet to be studied. Furthermore, to
our knowledge no studies have yet investigated the effectiveness of vitamin D3
supplementation on GA, as a biomarker of short-term glycemic control, among
individuals with or without diabetes. Despite lack of evidence on the relationship
between GA and vitamin D, HbA1c have been negatively linked to serum 25(OH)D level
(35-37). Clinical trials on vitamin D supplementation and its impact on glycemic
improvement (specifically on HbA1c) among individuals with type 2 diabetes, however,
could not consistently support the effectiveness of vitamin D supplementation on
glycemic control (38). It is not clear whether improvement in serum vitamin D may
improve Amadori formation of GA. We assume vitamin D may improve GA level via its
antioxidant properties. Furthermore, since vitamin D has a high binding affinity for
adipose tissue, it may prevent the GA-induced oxidative stress in adipocytes via its
antioxidant capabilities. Albumin is a transporter of vitamin D; therefore, binding of
vitamin D to serum albumin may affect its affinity to glucose under non-enzymatic
conditions. In that case, vitamin D may be effective in prevention of GA-derived AGEs
production.
Significance of the current study
To our knowledge, there is currently no studies that assessed the possible effects
of vitamin D3 supplementation on serum GA levels among individuals with or without
type 2 diabetes. While GA is a relatively new biomarker for type 2 diabetes management,
almost all the current studies on vitamin D supplementation in type 2 diabetes have been
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targeting fasting plasma glucose and HbA1c as the markers of glycemic control. The
findings from this study will help to fill the gap on the possible beneficial effects of
vitamin D3 on GA, as the most abundant Amadori-protein in human serum. Therefore,
the aim of this is study was to investigate and compare the effectiveness of daily
supplementation with 4000 IU and 6000 IU vitamin D3 for 3 months and 6 months on
GA.
Materials and methods:
In this clinical trial, we assessed the effect of daily supplementation with 4000
and 6000 IU of vitamin D3 over six months on glycated albumin (GA), albumin (ALB)
and GA% (GA to ALB ratio * 100) among adults with type 2 diabetes living in South
Florida. The parent study was conducted by Huffman et al. (39) assessing the effect of
vitamin D3 supplementation on cardiovascular disease biomarkers. In the present study,
serum samples were collected at baseline, 3 months and 6 months stored at -80˚ʿ were
used for measuring GA, ALB and GA%.
Study participants were recruited from 2 sources:
- From community areas by distributing flyers including the purpose of the study,
inclusion and exclusion criteria, and the investigators information.
- From 2 clinics: Borinquen Health care center and Clinical Care Medical
center. Weekly visits were conducted to recruit study participants.
Interested individuals called the investigators and expressed their willingness to
participate in the study and were asked to answer a few pre-screening questions.
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Qualified individuals were invited for screening at the Human Nutrition Laboratory,
Florida International University. After signing the informed consent form, fasting blood
samples were collected and screening questionnaires were administered to evaluate
whether the inclusion criteria were met (39).
Inclusion criteria were being 30-70 years old, being African-American or
Hispanic, having Type 2 diabetes, being vitamin D insufficient [25(OH)D3 < 30 ng/mL].
Exclusion criteria was being pregnant or lactating, taking vitamin D supplements,
injecting insulin, suffering from thyroid, hepatic and/or renal complications, suffering
from HIV, cancer. The duration of the intervention was 6 months and participants were
contacted at four time points:
Time zero (T0): Screening: During screening the eligibility of the participants to
enroll in the study was assessed based on the inclusion and exclusion criteria. Participants
signed an informed consent form before the data collection. Fasting blood was collected
for screening of vitamin D status.
Time one (T1): Baseline: All participants who met the inclusion criteria
participated in the study. Blood collection, anthropometric measurements, skin color
measurements, and a socio-demographic questionnaire were administered at baseline and
vitamin D supplements (pills) were provided to the participants (4000 and 6000 IU pills).
Time two (T2): Blood collection, anthropometric measurements, and skin color
measurements were administered after 3 months of supplementation with 4000 IU or
6000 IU vitamin D3 pills. Additional vitamin D3 pills were provided to the participants.
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Time three (T3): Blood collection, anthropometric measurements, and skin color
measurements were administered after 6 months of supplementation. Study was
terminated at this point.
Measurements of variables:
a. Socio-demographic questionnaire
A socio-demographic questionnaire was used to collect information about age,
gender, race/ethnicity, years living in the United States and years having type 2 diabetes.
b. Anthropometric measurements
Height and weight measurements were taken by using a SECA balance scale
(SECA Corp, Columbia, MD), to the nearest 0.5 cm and 0.1 kg, respectively. Waist
circumference was measured by using a measuring tape to the nearest 0.1 cm. All
measurements were done twice and the average of two readings was considered in the
analysis.
c. Skin exposure measurement
Reflectance colorimetry method was used to determine skin color as an objective
measure of skin sun exposure (IMS Smart Probe 400, Millford CT, USA) (39). This
instrument uses the International Commission on Illumination Scale and ranges the skin
color from 0 (black) to 100 (white). The measurement sites included 3 areas: wrist of the
right hand as the most exposed area to sun, inside of the right upper arm and the waist as
the least exposed areas to the sun (39). Each measurement was conducted 2 times and the
average was considered in the proposed study analysis. This tool is validated by several
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studies (39-40). Skin sun exposure level was determined by calculating the difference
between the wrist of the right hand skin color (the most exposed) and the inside of the
right upper arm (the least exposed).
d. Blood collection and analysis
Fasting venous blood was collected by a certified phlebotomist (15 mL). After
coagulation of blood samples in serum separator tubes for 30-45 minutes, samples were
centrifuged at 2500 RPM for 30 minutes to obtain the serum. Fasting plasma glucose
concentration was measured by hexokinase enzymatic method, glycated hemoglobin A1c
(HbA1c) was measured by using DCA2000 + system (BAYER Corporation, Diagnostics
Division, N.Y) and 25(OH)D3 concentrations were measured by using an enzymatic
immunoassay kit (Immunodiagnostic Systems Scottsdale, AZ) (16). C-reactive protein
(CRP) was measured Immulite (Diagnostic Products Corporation, Los Angeles, CA).
Insulin was determined by an enzymatic immunoassay kit (Millipore, St Charles, MZ).
e. Glycated albumin, albumin and GA%
Serum GA, ALB and GA% were measured by using GLYCABEN assay (Exocell
Inc., Philadelphia, PA, item No 1003). In this sandwich based enzyme linked
immunosorbent assay, glycated albumin is quantitatively determined by capturing the
binding of a specific immobilized monoclonal antibody, A717, to glycated albumin (4142). In this process, 100 μL of participants’s serum samples were mixed with 100 μL
Charcoal Extraction Buffer overnight (18-hours) at room temperature. After centrifuging
the mixture at 14K for 10 minutes, 100 μL of the supernatant were collected. To
neutralize the extracted serum samples, 100 μL Glycated Albumin Neutralizing Buffer
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were added to the collected samples and mixed. Samples were centrifuged at 14K for 1
minute.
To measure GA, the precoated Glycated Albumin Assay Plate was washed 8
times with wash buffer. Assay standards were prepared as instructed in the GLYCABEN
protocol. Then 50 μL Glycated Albumin Reaction Buffer was added to all the wells.
After adding 50 μL Glycated Albumin Diluent to the blank wells, 50 μL of assay
standards and assay control were added to the designated wells. Later, 50 μL of the
extracted and neutralized serum samples were added to the plate. Plate was incubated in
an incubation chamber at room temperature for 60 minutes. The plate was washed 8
times and 100 μL of TMB color developer was added to all the wells. After 10 minutes of
incubation at room temperature, 100 μL Acid Color Stopper was added to the wells. The
absorbance was determined at 450 nm by a plate reader located at Huffman Nutrition
Laboratory at Florida International University. Regression analysis was used to determine
the glycated albumin in each sample. Concentrations were expressed as mg/mL.
To measure total albumin (ALB), serial dilution of total albumin standards were
prepared as instructed in the GLYCABEN protocol. A non-coated plate was used for this
colorimetric assay. After adding 10 μL of purified water in the blank wells, 10 μL of the
standards were added to the standard well. Later, 10 μL of the extracted and neutralized
serum samples were added to the designated wells followed by 200 μL of Total Albumin
Reagent to all the wells. After 5 minutes incubation in the room temperature, the
absorbance was determined at 630 nm by a plate reader. Regression analysis was used to
determine the albumin levels. Concentrations were expressed as mg/mL.
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GA% was calculated by dividing the absolute concentration of GA (mg/mL) to
the total albumin concentration (mg/mL) multiplied by 100:
GA% = GA/ALB x 100%
Expected values measured by Glycaben for GA% for non-diabetic individuals is
estimated between 0.4% to 2.4%. For individuals with uncontrolled diabetes, GA% will
be >2.5%.
Statistical analysis:
The IBM statistical package for the social sciences (SPSS) version 20 (Chicago,
IL, USA) was used for performing the statistical analysis. Descriptive statistics were
conducted for baseline characteristics. Numerical normally distributed data and
categorical data were compared using paired t-test and Chi-Squared test, respectively.
The main outcome was GA%. Gender and time were input as categorical and the rest of
variables were input as continuous in the analysis. G*Power 3.0.10 software was used for
post-hoc power analysis. Mixed models were used to compare 4000 IU and 6000 IU/day
treatment groups. In this model, GA% was the dependent variable and supplementation
time was the independent variable. Covariates were age, BMI, sun exposure, fasting
plasma glucose, insulin and CRP. Factors included gender and treatment groups. To
compare the changes from baseline, three months and six months, Bonferroni multiple
comparison test was used at the statistical significance of P-value <0.05.
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Results
Seventy-seven out of 92 subject who were initially screened for this study, met
the inclusion criteria. Two participants were excluded due to missing values for sun
exposure. Sixty-eight participants completed the study. Values were tested for normal
distribution. Three subjects with outlier values for GA and ALB were excluded. A
sample of 65 participants, females (n = 40) and males (n = 25), were included in the
present study`s analysis. There were 44 participants in 4000 IU intervention group and 21
participants in the 6000 IU intervention group. Mean age was 54.52 ± 7.86 years. Mean
FPG at baseline, 3 months and 6 months were 186.478 ± 79.93, 184.52 ± 72.55, and
172.8 ± 71.4 mg/dL. There were no statistically significant differences in FPG from
baseline to 3 months (P=0.756), 3 months to 6 months (P=0.084) and baseline to 6
months (P=0.142). Mean HbA1c at baseline, 3 months and 6 months were 8.41 ± 2.31,
8.37 ± 2.03, and 8.30 ± 2.06 mg/dL. There were no statistically significant differences in
HbA1c from baseline to 3 months (P=0.806), 3 months to 6 months (P=0.701) and
baseline to 6 months (P=0.635). Mean insulin levels at baseline, 3 months and 6 months
were 12.63 ± 11.56, 11.64 ± 7.17, and 11.3 ± 7.35 mg/dL. There were no statistically
significant differences in insulin levels from baseline to 3 months (P=0.474), 3 months to
6 months (P=0.687) and baseline to 6 months (P=0.256). Mean CRP at baseline, 3
months and 6 months were 8.07 ± 10.81, 6.81 ± 7.3, and 7.13 ± 6.91 mg/dL. There were
no statistically significant differences in CRP from baseline to 3 months (P=0.271), 3
months to 6 months (P=0.701) and baseline to 6 months (P=0.425).
Unadjusted mean ± SD for serum 25(OH)D3 at baseline, 3 months and 6 months
were 22.4 ± 6.77, 40.4 ± 13.68, and 40.57 ± 14.55, respectively. Paired t-test analysis
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showed a statistically significant increase in 25(OH)D3 from baseline to 3 months
(P<0.001), and from baseline to 6 months (P< 0.001). There were no significant
differences between 25(OH)D3 levels at 3 months and 6 months (P=0.886). Mixed model
analysis did not show significant interactions between 2 intervention groups and study
time points regarding 25(OH)D3. Unadjusted mean ± SD for GA at baseline, 3 months
and 6 months were 1.51 ± 0.44, 1.47 ± 0.72, and 1.54 ± 0.34, respectively (Table 1).
Paired t-test analysis showed no statistically significant differences between GA levels at
baseline and 3 months (P=0.418), 3 months and 6 months (P=0.112), and baseline and 6
months (P=0.619). Mixed model analysis controlling for interactions between 4000 IU
and 6000 IU/day doses and outcome variables showed no differences between the two
treatment groups. Unadjusted mean ± SD for ALB at baseline, 3 months and 6 months
were 32.84 ± 05.69, 36.34 ± 7.36, and 35.66 ± 6.7, respectively (Table 1). Paired t-test
analysis showed statistically significant differences between ALB levels at baseline and 3
months (P=0.002), and at baseline and 6 months (P=0.009). There were no significant
differences between ALB levels at 3 months and 6 months (P=0.521). Mixed model
analysis controlling for interactions between 4000 IU and 6000 IU doses and outcome
variables showed no differences between the two treatment groups. Unadjusted pairwise
comparisons between ALB levels showed a statistically significant increase from baseline
to 3 months (P=0.003), and a statistically significant increase from baseline to 6 months
(P=0.031). After adjusting for covariates, including age, gender, BMI, sun exposure,
fasting plasma glucose, insulin and CRP, the model remained statistically significant for
baseline and 3 months (P=0.004) and baseline and 6 months (P=0.046).
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Unadjusted mean ± SD for GA% at baseline, 3 months and 6 months were 4.69 ±
1.7, 4.13 ± 1.09, and 4.42 ± 1.23, respectively. Paired t-test analysis showed statistically
significant differences between GA% at baseline and 3 months (P= 0.005). This
difference was not statistically significant for GA% at 3 months and 6 months (P= 0.068)
and GA% at baseline and 6 months (P= 0.208). Mixed model analysis controlling for
interactions between 4000 IU and 6000 IU/day doses and outcome variables showed no
differences between the two treatment groups. Unadjusted pairwise comparisons between
GA% were statistically significant from baseline to 3 months (P=0.015), and from 3
months to 6 months (P=0.039), but not from baseline to 6 months (P= 0.488). After
adjusting for covariates, including age, gender, BMI, sun exposure, fasting plasma
glucose, insulin and CRP, the change remained statistically significant for baseline and 3
months (P= 0.018) but not for 3 months to 6 month (P= 0.069), nor for baseline and 6
months (P= 0.471).
Discussion
To our knowledge the present study is the first to assess the effects of vitamin D3
supplementation on serum glycated albumin (GA%) among human subjects with or
without type 2 diabetes. Most of the previous studies investigated the effects of vitamin
D3 on HbA1c (38, 43-51). The results of the present study showed that daily
supplementation with 4000 IU and 6000 IU of vitamin D3 to individuals with type 2
diabetes could significantly increase serum 25(OH)D3 after 3 months (P< 0.001).
However, after reaching the sufficient level of vitamin D level (>20 ng/mL) in 3 months,
the same dose of supplementation could not significantly change serum 25(OH)D3 from
3 months to 6 months. We observed the same change pattern for GA%. GA% is a

84

relatively new biomarker of glycemic control and oxidative stress. GA half-life is shorter
than HbA1c (2-3 weeks for GA% compared to 2-3 months for HbA1c) and it is believed
to be a more sensitive biomarker of glycemic status compared to HbA1c. Our results
showed a statistically significant decrease in GA% after 3 months of supplementation
with vitamin D3, with both 4000 IU and 6000 IU/day dosages. However, from 3 months
to 6 months, there was a significant increase in GA%. Furthermore, the present study did
not find a significant association between serum 25(OH)D3 and GA%. This may be due
to small sample size of the current study and low power.
Overall, we could not detect a significant change in GA% from baseline to 6
months. This is consistent with our findings regarding HbA1c; we could not find a
statistically significant change in HbA1c with vitamin D3 supplementation over 6 months
(nor for 3 months). Madar et al (38) also reported no significant improvements in HbA1c
and fructosamine after 16 week of vitamin D3 supplementation to healthy individuals
with insufficient vitamin D levels. In this randomized double-blinded placebo-controlled
study in Norway, 251 immigrants aged 18-50 years were assigned to receive 400 IU (n =
85), 1000 IU (n = 84), or placebo (n = 82). Although we found similar results with
HbA1c and GA% over 6 months of oral supplementation with higher doses of vitamin
D3, we found significant decrease in GA% from baseline to 3 months. There were several
differences in design between our study and Madar et al. (38). Madar’s did not measure
fructosamine levels after 3 months of supplementation with vitamin D. This trial was
conducted among a younger group of individuals without type 2 diabetes. Comparing
GA% with fructosamine, it is believed that GA% is a more sensitive diagnostic tool than
fructosamine (13). Furthermore, knowing fructosamine is predominantly a measure of

85

GA, adjustment for abnormal albumin levels should be considered to obtain accurate
measures of nonenzymatic glycation of extracellular proteins.
A recent systematic review of 12 interventional and 7 observational studies on the
effect of vitamin D on type 2 diabetes reported that there is not sufficient evidence
supporting the beneficial effects of vitamin D supplementation on glycemic control
among patients with type 2 diabetes (43), this conclusion was reached despite cumulative
evidence on the direct and indirect role of vitamin D in glucose metabolism and the
established association between serum vitamin D status and glycemic status. More
specifically, the systematic review concluded that daily supplementation with lower than
6000 IU/day vitamin D (38, 44-45), supplementation with 400-5600 IU/day vitamin D for
less than 6 months (38, 46), and supplementation with vitamin D among individuals with
well-managed type 2 diabetes or sufficient serum vitamin D levels did not improve
biomarkers of glucose metabolism (43). In contrast; we found significant improvement in
GA% in the first phase of study (baseline to 3 months), when participants had
hypovitaminosis D. When participants reached the sufficiency level (> 20 ng/mL) at 3
months, there were no further improvements in GA% from 3 months to 6 months.
It has been suggested that supplementation with more than 4000 IU of vitamin D
may have beneficial effects on serum FPG, HbA1c and insulin resistance among
individuals with type 2 diabetes (47). In a recent meta-analysis of 24 controlled trials,
Mirhosseini et al. (47) indicated insufficient evidence regarding the improvement in
glycemic control with vitamin D supplementation might be due to insufficient dose of
vitamin D (< 4000 IU/day), short duration of supplementation, high BMI and small study
sample size (47). Obesity has inverse effects on serum 25(OH)D (48). As vitamin D is a
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fat-soluble vitamin, it can get trapped in the fat tissue and become less biologically
available to the body. Vimaleswaran et al. (49) reported a 1.15% decrease in serum
25(OH)D3 for each kg/m² increase in BMI. It is suggested that obese people with
insufficient vitamin D level should take 2-3 times higher doses of vitamin D to replenish.
A recent prospective observational cohort study found a significant decrease in
HbA1c with vitamin D3 supplementation for 9 months (50). This study was conducted
among 1000 individuals with type 1 and type 2 diabetes. The supplementation dosage in
this study was not revealed in the article (50). Although we cannot compare this study
with ours based on the vitamin D supplementation dosage, their extended study duration
may suggest vitamin D supplementation for longer periods than 6 months may have
beneficial effects on glycemic control outcomes in individuals with diabetes.
In a community-based longitudinal study among 1018 individuals without type 2
diabetes, the effect of vitamin D supplementation alone, and vitamin supplementation in
combination with other nutrients on glycemic status was assessed (51). First group (n
=223) received daily supplementation of 1000-20,000 IU/day vitamin D3, as needed to
achieve the target serum 25(OH)D3 level, and group 2 (n = 790) was assigned to 100020,000 IU/day with vitamin D3 and additional supplements (omega-3 fatty acids, vitamin
C, magnesium, caprylic acid, PolyGlycopleX and probiotics). The results of this study
showed significant increase in serum 25(OH)D3 in both groups over the period of 12
months. HbA1c and CRP were significantly reduced only among group 2, after 12
months of supplementation. Larger decrease in HbA1c and CRP levels were associated
with higher 25(OH)D3 level after 12 months. The results of this study suggested that
participants in group 2 were less likely to develop prediabetes/diabetes, compared to
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participants in group 1 (8% vs. 16%). Furthermore, 44% of subjects with prediabetes in
group 2 improved to normoglycemic after 12 months, compared to 8% in group 1. This
study concluded that vitamin D supplementation in combination with other nutrients may
have beneficial effects on glycemic control and reduce the risk of diabetogenesis (51).
Conclusion
Daily supplementation with higher doses of vitamin D3 (>4000 IU) may have
beneficial effects on health status of individuals with type 2 diabetes. GA% may be a
more sensitive biomarker for oxidative/glycemic changes in individuals with type 2
diabetes and hypovitaminosis D. The limitations of the study included small sample size,
lack of a control group, shorter duration of the study, and utilization of frozen serum
samples to measure GA. The strengths of the study were its novelty to assess the effect of
vitamin D3 supplementation on less studied biomarkers of glycemic/oxidative status and
the ability to compare two different doses of vitamin D3 supplementation. Larger studies
with longer durations among different racial and ethnic groups with and without diabetes
may help to confirm the benefits of vitamin D3 supplementation on oxidative and
glycemic health outcomes.
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Table 1. Participants`s characteristics at baseline
Mean ± SD
(N= 65)
54.52 ± 7.86

Variable

Age (years)
Gender n (%)
Female
40 (62 )
Male
25 (38)
Dosage n (%)
4000 IU
44 (68)
6000 IU
21 (32)
BMI (kg/m2)
33.57 ± 6.5
Skin sun exposure score
4.2 ± 4.02
25(OH)D3 (ng/mL)
22.4 ± 6.77
FPG (mg/dL)
186.478 ± 79.93
HbA1c (%)
8.41 ± 2.31
Insulin (mg/dL)
12.63 ± 11.56
CRP (mg/dL)
8.06 ± 10.81
GA (mg/mL)
1.51 ± 0.44
ALB (mg/mL)
32.84 ± 05.69
GA%
4.69 ± 1.7
Data are mean ± (SD) or %. BMI = Body mass index. HbA1c =
glycated hemoglobin. CRP = C-reactive protein. GA = glycated
albumin. ALB = serum total albumin. GA% = (GA/ALB)%.
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Table 2. Mixed model comparisons of repeated measures at baseline, after 3 months and
after 6 months without adjustment for covariates.
Variable
ALB (mg/mL)
Baseline
3 months
6 months

Mean ± SE
(N = 65)

P-value

33.08 ± 0.74
36.67 ± 0.96
35.52 ± 0.89

*0.003
*0.031

4.58 ± 0.19
4.07 ± 0.14
4.43 ± 0.16

*0.015
*0.039

22.49 ± 0.897
41.96 ± 1.71
41.46 ± 1.91

*<0.001
*<0.001

GA%
Baseline
3 months
6 months
25(OH)D3 (ng/mL)
Baseline
3 months
6 months

Data represented by mean ± standard error. * P-values are from multiple comparisons
with Bonferroni correction. Statistically significance from baseline. P<0.05 is considered
significant. Time and dosage interactions were not significant for any of the variables
included in table 2. GA=glycated albumin. GA% = (GA/ALB)%.
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Table 3. Mixed model comparisons of repeated measures at baseline, after 3 months and
after 6 months with adjustment for covariates.
Mean ± SD
(N = 65)
ALB (mg/mL)
Baseline
3 months
6 months

P-value

33.02 ± 0.74
36.51 ± 0.96
35.42 ± 0.87

0.004*
0.046*

4.58 ± 0.19
4.09 ± 0.141
4.41 ± 0.173

0.018*
0.471

GA%
Baseline
3 months
6 months

Data represented by mean ± standard error. *P-values are from multiple comparisons
with Bonferroni correction. Statistically significance from baseline. P<0.05 is considered
significant. GA=glycated albumin. ALB=serum total albumin. GA%=(GA/ALB)%. Time
and dosage interactions were not significant for ALB and GA%. Mixed model analysis
was adjusted for age, gender, BMI, sun exposure, fasting plasma glucose, insulin and
CRP.
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CHAPTER V: SUMMARY AND CONCLUSIONS

The results of the present study showed that pro-inflammatory dietary intakes
may be associated with increased risk of hypo-insulinemia and incidence of higher SBP
among individuals with type 2 diabetes and vitamin D deficiency/insufficiency.
Furthermore, we showed daily oral supplementation with higher doses of vitamin D,
4000 IU and 6000 IU/day compared to the recommended dose of 600 IU/day, for 6
months may improve oxidative stress status among a group of individuals with type 2
diabetes and vitamin D deficiency/insufficiency. Serum 8-OHdG may be a predictive
biomarker of DNA/RNA damage among individuals with type 2 diabetes. Our results
showed no improvements in 8-OHDdG after 3 months of supplementation with vitamin
D among individuals with vitamin D deficiency/insufficiency. This may suggest that
longer supplementation durations than 3 months should be considered for interventions
among individuals with vitamin D insufficiency/deficiency. We did not find significant
changes in sun exposure during the 6 month period of this study. This study suggests
daily supplementation with higher doses of vitamin D3, 4000 IU and 6000 IU/day
compared to the recommended dose of 600 IU/day, may have further beneficial effects on
health status of individuals with type 2 diabetes. Vitamin D supplementation for 3 months
may decrease the GA% among individuals with type 2. This study showed that GA%
change pattern followed 25OHD change pattern inversely: As 25OHD increased from
baseline to 3 months, GA% decreased. When 25OHD remained unchanged from 3
months to 6 months, GA% did not change significantly. Based on the present study`s
results, GA% may be a more sensitive biomarker for oxidative/glycemic changes in
individuals with type 2 diabetes and hypovitaminosis D.
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In summary, daily oral supplementation with higher doses of vitamin D, 4000 IU
and 6000 IU/day compared to the recommended dose of 600 IU/day, and antiinflammatory dietary intakes may have beneficial effects on health status of individuals
with type 2 diabetes and vitamin D deficiency/insufficiency. The results of this study may
serve as a basis for the future nutrition interventions to improve the dietary inflammatory
intake and health status of individuals with type 2 diabetes. Larger studies with longer
durations among different racial and ethnic groups with and without diabetes may help to
confirm the benefits of vitamin D3 supplementation and anti-inflammatory dietary
patterns on oxidative and glycemic health outcomes.
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Appendix 2: Short Food Frequency Questionnaire
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Appendix 3: Skin Color and Anthropometrics Record Form
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